US20210309997A1 - Modified peptide nucleic acid compositions - Google Patents

Modified peptide nucleic acid compositions Download PDF

Info

Publication number
US20210309997A1
US20210309997A1 US17/218,145 US202117218145A US2021309997A1 US 20210309997 A1 US20210309997 A1 US 20210309997A1 US 202117218145 A US202117218145 A US 202117218145A US 2021309997 A1 US2021309997 A1 US 2021309997A1
Authority
US
United States
Prior art keywords
compound
study
circumflex over
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/218,145
Other languages
English (en)
Inventor
Danith H. LY
Shivaji A. Thadke
Ramesh U. BATWAL
Valentina DI CARO
Dietrich A. Stephan
Letha J. Sooter
Samuel I. Backenroth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neubase Therapeutics Inc
Original Assignee
Neubase Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neubase Therapeutics Inc filed Critical Neubase Therapeutics Inc
Priority to US17/218,145 priority Critical patent/US20210309997A1/en
Priority to US17/232,001 priority patent/US11603530B2/en
Priority to US17/232,000 priority patent/US20220112238A1/en
Priority to US17/231,998 priority patent/US20210309700A1/en
Priority to US17/231,997 priority patent/US20210324012A1/en
Assigned to NEUBASE THERAPEUTICS, INC. reassignment NEUBASE THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STEPHAN, DIETRICH A., BACKENROTH, SAMUEL I., BATWAL, Ramesh U., DI CARO, Valentina, LY, DANITH H., SOOTER, LETHA, THADKE, Shivaji
Publication of US20210309997A1 publication Critical patent/US20210309997A1/en
Assigned to NEUBASE THERAPEUTICS, INC. reassignment NEUBASE THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Thadke, Shivaji A., SOOTER, LETHA J.
Priority to US18/102,415 priority patent/US20230174985A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Definitions

  • HD Huntington's disease
  • HTT huntingtin
  • the present disclosure provides a compound comprising a chain, wherein the chain comprises a series of atoms concatenated to form the chain, wherein a plurality of the atoms that are concatenated to form the chain are each independently substituted with a substituent that bears a guanidino group, wherein the chain has a pattern of one atom that is independently substituted with a substituent that bears a guanidino group, followed by five consecutive atoms that are not substituted by a substituent that bears a guanidino group, followed by a second atom that is independently substituted with a substituent that bears a guanidino group, followed by another five consecutive atoms that are not substituted by a substituent that bears a guanidino group, followed by a third atom that is independently substituted with a substituent that bears a guanidino group, wherein a first end of the chain or a second end of the chain is substituted with
  • the present disclosure provides a compound comprising a peptide nucleic acid sequence and a cell permeabilizing group attached to the peptide nucleic acid sequence, wherein if a radiolabeled analogue of the compound is subjected to an assay, wherein the assay comprises:
  • the present disclosure provides a compound comprising a peptide nucleic acid sequence, wherein the peptide nucleic acid sequence comprises: (i) a series of peptide nucleic acid residues having a repeating triad of nucleobase side chains; and (ii) a cell permeabilizing group attached to the series of peptide nucleic acid residues, wherein if the compound is subjected to an assay, and the assay comprises:
  • the present disclosure provides a compound comprising a peptide nucleic acid sequence, wherein the peptide nucleic acid sequence comprises: (i) a series of peptide nucleic acid residues having a repeating triad of nucleobase side chains; and (ii) a cell permeabilizing group attached to the series of peptide nucleic acid residues, wherein if the compound is subjected to an assay, and the assay comprises:
  • the present disclosure provides a compound comprising a peptide nucleic acid sequence, wherein the peptide nucleic acid sequence comprises: (i) a series of peptide nucleic acid residues having a repeating triad of nucleobase side chains; and (ii) a cell permeabilizing group attached to the series of peptide nucleic acid residues, wherein if the compound is subjected to a plasma protein binding assay, and the plasma protein binding assay comprises:
  • the present disclosure provides a compound having the formula (I):
  • the present disclosure provides a method of treating a condition in a subject, the method comprising administering to the subject a therapeutically-effective amount of any compound of the disclosure.
  • FIG. 1 illustrates cumulative excretion of radioactivity following a single intravenous bolus of [ 14 C]-Compound 1 to a male cynomolgus monkeys at 5 mg/kg (Animal 103).
  • FIG. 2 illustrates individual blood and plasma profiles of total radioactivity following a single intravenous bolus of [ 14 C]-Compound 1 to a male cynomolgus monkeys at 5 mg/kg in Animal 101 (4 hours post dose, Panel A), Animal 102 (12 hours post dose, Panel B), Animal 103 (24 hours post-dose, Panel C) and Animal 103 (168 hours post-dose, Panel D).
  • FIG. 3 illustrates concentrations of total radioactivity in representative organs and tissues at various times following a single intravenous bolus of [ 14 C]-Compound 1 to male cynomolgus monkeys at 5 mg/kg.
  • FIG. 4 illustrates concentrations of total radioactivity in representative organs and tissues at various times following a single intravenous bolus of [ 14 C]-Compound 1 to male cynomolgus monkeys at 5 mg/kg.
  • FIG. 5 illustrates tissue to blood ratios at various times following a single intravenous bolus of [ 14 C]-Compound 1 to male cynomolgus monkeys at 5 mg/kg.
  • FIG. 6 illustrates tissue to blood ratios at various times following a single intravenous bolus of [ 14 C]-Compound 1 to male cynomolgus monkeys at 5 mg/kg.
  • FIG. 7A and FIG. 7B are autoradiographs that depict representative tissue distribution of total radioactivity in parasagittal sections of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 8A and FIG. 8B are autoradiographs that depict representative tissue distribution of total radioactivity in sagittal sections of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 9A and FIG. 9B are autoradiographs that depict representative tissue distribution of total radioactivity in sagittal sections of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 10A and FIG. 10B are autoradiographs that depict representative tissue distribution of total radioactivity in sagittal sections of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 11 is an autoradiograph that depicts representative tissue distribution of total radioactivity in a mid-sagittal section of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 12A and FIG. 12B are autoradiographs that depict representative tissue distribution of total radioactivity in sagittal sections of Animal 101 (4 hours post dose), Animal 102 (12 hours post dose), Animal 103 (7 days post dose) following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 13 are autoradiographs that depict representative cranial tissue distribution of total radioactivity in selected sagittal sections of Animal 101 (4 hours post dose), Animal 102 (12 hours post dose), Animal 103 (7 days post dose) following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 14 are autoradiographs that depict representative pelvic-area tissue distribution of total radioactivity in selected sagittal sections of Animal 101 (4 hours post dose), Animal 102 (12 hours post dose), Animal 103 (7 days post dose) following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 15A illustrates a mean brain concentration vs time profile of Compound 1 in C57BL6J mice administered doses of 0.3 mg/kg
  • FIG. 15B illustrates mean brain concentration vs time profile of Compound 1 in mice administered doses of 0.6 mg/kg
  • FIG. 15C illustrates mean brain concentration vs time profile of Compound 1 in C57BL6J mice administered doses of 1 mg/kg.
  • FIG. 16A illustrates mean spleen concentration vs time profile of Compound 1 in C57BL6J mice administered doses of 0.3 mg/kg
  • FIG. 16B illustrates mean spleen concentration vs time profile of Compound 1 in mice administered doses of 0.6 mg/kg
  • FIG. 16 C illustrates mean spleen concentration vs time profile of Compound 1 in C57BL6J mice administered doses of 1 mg/kg.
  • FIG. 17 illustrates mean heart concentration vs time profile of Compound 1 in C57BL6J mice administered doses of 0.3 mg/kg.
  • FIG. 18A illustrates mean brain, spleen, and heart concentrations vs time profile of Compound 1 in C57BL6J mice administered doses of 0.3 mg/kg
  • FIG. 18B illustrates mean brain, spleen, and heart concentrations vs time profile of Compound 1 in C57BL6J mice administered doses of 0.6 mg/kg
  • FIG. 18C illustrates mean brain, spleen, and heart concentrations vs time profile of Compound 1 in C57BL6J mice administered doses of 1 mg/kg.
  • FIG. 19A shows the relative expression of wtHTT (darker bars) and mHTT (lighter bars) by GM09197 cells after treatment with Compound 2 at 1 or 5 ⁇ M.
  • FIG. 19B shows the relative expression of wtHTT (darker bars) and mHTT (lighter bars) by GM09197 cells after treatment with Compound 3 at 1 or 5 ⁇ M.
  • FIG. 19C shows the relative expression of wtHTT (darker bars) and mHTT (lighter bars, not visible) by GM09197 cells after treatment with Compound 4 at 1 or 5 ⁇ M.
  • the mHTT bars are not visible as mHTT was below the limit of detection.
  • FIG. 20A shows the results of a cytotoxicity assay evaluating the percent of dead GM09197 cells present after mock-treatment (PBS, control) or treatment with Compound 2 at 1 or 5 ⁇ M.
  • FIG. 20B shows the results of a cytotoxicity assay evaluating the percent of dead GM09197 cells present after mock-treatment (PBS, control) or treatment with Compound 3 at 1 or 5 ⁇ M.
  • FIG. 20C shows the results of a cytotoxicity assay evaluating the percent of dead GM09197 cells present after mock-treatment (PBS, control) or treatment with Compound 4 at 1 or 5
  • FIG. 21A depicts the structural formula of Compound 1.
  • FIG. 21B depicts the structural formula of [ 14 C]Compound 1.
  • FIG. 22A depicts the structural formula of Compound 2.
  • FIG. 22B depicts the structural formula of Compound 4.
  • FIG. 23 depicts the structural formula of Compound 3.
  • Huntington's disease is a genetic disease associated with an abnormally long CAG repeat expansion in the huntingtin gene (HTT), which codes for the huntingtin protein (HTT). HTT genes that contain repeat lengths beyond a certain threshold produce mutant huntingtin protein (mHTT), which can induce pathological changes in the central nervous system. The risk, penetrance, and age of disease onset can be correlated with length of the HTT repeat expansion. Repeat counts of less than 27 CAG triads are associated with normal phenotype, while repeat counts from 27 to 35 generally confer normal phenotype but enhanced risk of disease in offspring. 36 to 39 repeats are associated with incomplete or reduced penetrance, with disease symptoms manifesting later in adult life, if at all. Repeat lengths greater than 40 confer full penetrance, while repeat counts of greater than 60 produce disease that can manifest as early as childhood.
  • the present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA.
  • the present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.
  • compounds of the disclosure bind CAG repeats within the mutant mHTT transcript present in Huntington's disease, thereby modulating expression of mHTT protein.
  • the disclosure provides a compound comprising a chain.
  • the chain can comprise a series of atoms concatenated to form the chain.
  • a plurality of the atoms that are concatenated to form the chain can be independently substituted with a substituent that bears a polar group, which can be, for example, a guanidino group.
  • the chain can have a pattern of one atom that is independently substituted with a substituent that bears a polar group, followed by five consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a second atom that is independently substituted with a substituent that bears a polar group, followed by another five consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a third atom that is independently substituted with a substituent that bears a polar group.
  • the chain has a pattern of one atom that is independently substituted with a substituent that bears a polar group (e.g., guanidino group), followed by seventeen consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a second atom that is independently substituted with a substituent that bears a polar group, followed by another seventeen consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a third atom that is independently substituted with a substituent that bears a polar group.
  • a polar group e.g., guanidino group
  • the third atom that is independently substituted with a substituent that bears a polar group is followed by eleven consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a fourth atom that is independently substituted with a substituent that bears a polar group.
  • the fourth atom that is independently substituted with a substituent that bears a polar group is followed by another eleven consecutive atoms that are not substituted by a substituent that bears a polar group.
  • the first atom, the second atom, and the third atom are each gamma carbons of a peptide nucleic acid oligomer.
  • the first atom, the second atom, and the third atom are each alpha carbons of a peptide nucleic acid oligomer.
  • the chain can have a pattern of one atom that is independently substituted with a substituent that bears a polar group (e.g., guanidino group), followed by eleven consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a second atom that is independently substituted with a substituent that bears a polar group, followed by another eleven consecutive atoms that are not substituted by a substituent that bears a polar group, followed by a third atom that is independently substituted with a substituent that bears a polar group.
  • a polar group e.g., guanidino group
  • Suitable polar groups can include groups that bear a formal charge at physiological pH, such as a guanidino group.
  • each substituent that bears a guanidino group is independently guanidinoalkyl.
  • each substituent that bears a guanidino group is independently guanidino(C 1 -C 4 )alkyl.
  • each substituent that bears a guanidino group is 2-guanidino-eth-1-yl.
  • each substituent that bears a guanidino group is 3-guanidino-prop-1-yl.
  • each substituent that bears a guanidino group is 4-guanidino-but-1-yl.
  • the pattern can further comprise one atom that is independently substituted with a substituent that bears a first nucleobase, followed by five consecutive atoms that are not substituted by a substituent that bears a nucleobase, followed by a second atom that is independently substituted with a substituent that bears a second nucleobase, followed by another five consecutive atoms that are not substituted by a substituent that bears a nucleobase, followed by a third atom that is independently substituted with a substituent that bears a third nucleobase.
  • the substituent that bears the first nucleobase, the substituent that bears the second nucleobase, and the substituent that bears the third nucleobase are each independently purinylacyl, purinylalkylene, pyrimidinylacyl, or pyrimidinylalkylene.
  • the substituent that bears the first nucleobase, the substituent that bears the second nucleobase, and the substituent that bears the third nucleobase are each independently guaninylacyl, adeninylacyl, cytosinylacyl, thyminylacyl, or uracilylacyl.
  • the first nucleobase, the second nucleobase, and the third nucleobase form a sequence that is CTG, TGC, or GCT.
  • a compound of the disclosure can be resistant to degradation by enzymes (e.g. nucleases or proteases).
  • the compound can be stable in a subject.
  • a compound of the disclosure can be water-soluble.
  • the compound can be endocytosed by a cell comprising a target sequence of the compound.
  • the compound is endocytosed, pinocytosed, phagocytosed in a cell that does not contain the target sequence.
  • the compound is transcytosed across the endothelia lining of the cerebral vasculature, or “blood-brain barrier.”
  • the compound comprises a peptide nucleic acid domain.
  • Peptide nucleic acids are oligonucleotide analogues that comprise a chain of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds, where the glycyl nitrogen of one or more units is functionalized with an alkylene or acyl group bearing a nucleobase.
  • Peptide nucleic acids can optionally comprise substitution on the N-(2-aminoethyl)-glycine backbone, for example:
  • substituents R ⁇ , R ⁇ , R ⁇ are alpha, beta, and gamma substituents, respectively.
  • the peptide nucleic acid chain is substituted with a polar group, such as a group that comprises a guanidino moiety.
  • the polar group can be bound to the alpha or gamma position of at least one peptide nucleic acid subunit.
  • a compound of the disclosure can comprise a chain of atoms with termini that are substituted or unsubstituted.
  • a first end of the chain and a second end of the chain can be each independently unsubstituted or substituted with an amino acid.
  • a first end of the chain and a second end of the chain can be each independently unsubstituted or substituted with a peptide.
  • the compound is a peptide nucleic acid oligomer, wherein the first end of the chain is an N-terminus of the peptide nucleic acid oligomer, and the second end of the chain is a C-terminus of the peptide nucleic acid oligomer.
  • the C-terminus of the peptide nucleic acid oligomer is bound by a peptide bond to a peptide, which can be for example, a sequence comprising alpha amino acid residues, beta amino acid residues, gamma amino acid residues, or a combination thereof.
  • the C-terminus of the peptide nucleic acid oligomer is bound by a peptide bond to amidated lysine. In some embodiments, the C-terminus of the peptide nucleic acid oligomer is bound by a peptide bond to amidated beta-lysine.
  • the C-terminus or N-terminus of the peptide nucleic acid is substituted with a cell-permeabilizing group.
  • the cell permeabilizing group is a polypeptide comprising 3 to 8 lysine residues.
  • the polypeptide is linked to the peptide nucleic acid via an amide bond.
  • the polypeptide is linked to the peptide nucleic acid via a peptide bond, a disulfide bond, or a linker comprising two penicillamine residues bound by a disulfide bond.
  • the compound can comprise from 4 to 10 guanidino groups. In some embodiments, the compound can comprise from 6 to 8 guanidino groups. In some embodiments, the compound can comprise from 7 to 9 guanidino groups. In some embodiments, the compound can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more guanidino groups. Each of the three guanidino groups can be independently bound to the peptide nucleic acid chain. In some embodiments, the group that comprises a guanidino moiety is a 4-guanidino-but-1-yl group, a 3-guanidino-prop-1-yl group, or a 2-guanidino-eth-1-yl group.
  • a sequence of the peptide nucleic acid domain comprises (GCT) n , wherein n is 1-10. In some embodiments, a sequence of the peptide nucleic acid domain is domain (GCT) 6 G. In some embodiments, a sequence of the peptide nucleic acid domain is GCTGCT. In some embodiments, a sequence of the peptide nucleic acid domain is CTGCTG.
  • a compound of the disclosure can comprise a moiety that improves cell-permeability of the compound relative to a molecule without the moiety that is otherwise identical to the compound.
  • a compound of the disclosure can reach an intracellular target within the cytoplasm or nucleus.
  • the disclosure provides a compound comprising a pharmacophore region attached to a multiply-positively charged region, wherein:
  • the present disclosure provides a compound represented by the structure of formula (I):
  • each nucleobase B is independently guanine, thymine, or cytosine. In some embodiments, B is guanine. In some embodiments, B is thymine. In some embodiments, B is cytosine. In some embodiments, B is adenine. In some embodiments, B is uracil. In some embodiments, each nucleobase B is an analog of a naturally occurring nucleobase.
  • At least one R 1 is guanidino(C 1 -C 4 )alkyl. In some embodiments, more than one R 1 is guanidino(C 1 -C 4 )alkyl. In some embodiments, at least one every other R 1 is guanidino(C 1 -C 4 )alkyl. In some embodiments, at least one every third R 1 is guanidino(C 1 -C 4 )alkyl. In some embodiments, at least one every second or third R 1 is guanidino(C 1 -C 4 )alkyl. In some embodiments, each R 1 is guanidino(C 1 -C 4 )alkyl.
  • At least one R 1 is 4-guanidinobut-1-yl. In some embodiments, at least one R 1 is 3-guanidinoprop-1-yl. In some embodiments at least one R 1 is 2-guanidino-eth-1-yl. In some embodiments, at least one R 1 is hydrogen. In some embodiments, each R 1 is hydrogen.
  • At least one R 2 is guanidino(C 1 -C 4 )alkyl. In some embodiments, more than one R 2 is guanidino(C 1 -C 4 )alkyl. In some embodiments, at least one every other R 2 is guanidino(C 1 -C 4 )alkyl. In some embodiments, at least one every third R 2 is guanidino(C 1 -C 4 )alkyl. In some embodiments, at least one every second or third R 2 is guanidino(C 1 -C 4 )alkyl. In some embodiments, each R 2 is guanidino(C 1 -C 4 )alkyl.
  • At least one R 2 is 4-guanidinobut-1-yl. In some embodiments, at least one R 2 is 3-guanidinoprop-1-yl. In some embodiments at least one R 2 is 2-guanidino-eth-1-yl. In some embodiments, at least one R 2 is hydrogen. In some embodiments, each R 2 is hydrogen.
  • G is N
  • R 5 is the water-solubilizing group.
  • the water-solubilizing group is a multiply-positively charged region that comprises at least six consecutive building blocks.
  • each of the consecutive building blocks independently comprises a side chain that carries a positive formal charge at neutral pH.
  • R 3 is hydrogen. In some embodiments, R 3 is an amino(C 1 -C 4 )alkyl. In some embodiments, R 3 is 4-aminobut-1-yl. In some embodiments, R 3 is 3-aminoprop-1-yl. In some embodiments, m is 0. In some embodiments, m is 1.
  • R 4 is hydrogen. In some embodiments, R 4 is a sequence comprising at least one alpha amino acid residue. In some embodiments, R 4 is a sequence comprising at least one beta amino acid residue. In some embodiments, R 4 is a sequence comprising at least one gamma amino acid residue. In some embodiments, R 4 is
  • R 4 is
  • p is 3, 4, 5, 6, 7, or 8. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8.
  • R 5 is hydrogen
  • R 5 is
  • R 7 is a side chain of an alpha amino acid. In some embodiments, R 7 is a side chain of an beta amino acid. In some embodiments, R 7 is a side chain of a gamma amino acid. In some embodiments, q is 0. In some embodiments, q is 1.
  • R 5 is
  • R 5 is
  • the water solubilizing group comprises a structure that has multiple formal charges at physiological pH.
  • R 5 is the multiple formal charges are positive charges.
  • R 1 and R 2 are a side chain of a natural amino acid or a guanidino(C 1 -C 4 )alkyl, and R 5 is not hydrogen.
  • R 5 is the sequence comprising at least one alpha amino acid residue.
  • the compound has the formula:
  • n is 6. In some embodiments, at least one R 1 is 4-guanidinobut-1-yl. In some embodiments, each R 1 is 4-guanidinobut-1-yl. In some embodiments, at least one R 2 is hydrogen. In some embodiments, each R 2 is hydrogen. In some embodiments, R 3 is 4-aminobut-1-yl. In some embodiments, R 3 is 3-aminoprop-1-yl. In some embodiments, R 4 is hydrogen. In some embodiments, R 5 is hydrogen. In some embodiments, R 5 is
  • the compound has the formula:
  • n 1 is 2.
  • the compound comprises the sequence (CTG) 2 .
  • at least one R 1 is 4-guanidinobut-1-yl.
  • each R 1 is 4-guanidinobut-1-yl.
  • at least one R 1 is hydrogen.
  • R 3 is 4-aminobut-1-yl.
  • R 3 is 3-aminoprop-1-yl.
  • the compound has the formula:
  • B 1a is cytosine
  • B 2a is thymine
  • B 3a is guanine
  • n 1 is 2.
  • the compound has the formula:
  • the compound has the formula:
  • n is 6.
  • the compound comprises the sequence (CTG) 2 .
  • at least one R 1 is 4-guanidinobut-1-yl.
  • each R 1 is 4-guanidinobut-1-yl.
  • at least one R 1 is hydrogen.
  • R 3 is 4-aminobut-1-yl.
  • R 3 is 3-aminoprop-1-yl.
  • the compound has the formula:
  • n 2 is 2.
  • R 1 is 4-guanidinobut-1-yl.
  • R 3 is 4-aminobut-1-yl.
  • R 3 is 3-aminoprop-1-yl.
  • the compound has the formula:
  • B 1b is cytosine
  • B 2b is thymine
  • B 3b is guanine
  • n 2 is 2.
  • the compound has the formula:
  • the compound has the formula:
  • the compound has the formula:
  • n is 10. In some embodiments, n is 11. In some embodiments, n is 12. In some embodiments, n is 13. In some embodiments, n is 14. In some embodiments, n is 15. In some embodiments, n is 16. In some embodiments, n is 17. In some embodiments, n is 18. In some embodiments, n is 19. In some embodiments, n is 20.
  • At least one R 1 is hydrogen. In some embodiments, n is greater than 1, and every other R 1 is hydrogen. In some embodiments, at least one R 1 is 4-guanidinobut-1-yl. In some embodiments, n is greater than 1, and every other R 1 is 4-guanidinobut-1-yl.
  • At least one R 2 is hydrogen. In some embodiments, each R 2 is hydrogen. In some embodiments, at least one R 2 is 4-guanidinobut-1-yl. In some embodiments, every other R 2 is 4-guanidinobut-1-yl.
  • R 3 is 4-aminobut-1-yl. In some embodiments, R 3 is 3-aminoprop-1-yl.
  • R 4 is hydrogen. In some embodiments, R 4 is
  • p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8.
  • R 5 is hydrogen. In some embodiments, R 5 is
  • R 5 is
  • R 6 is 4-aminobut-1-yl. In some embodiments, R 6 is 3-aminoprop-1-yl.
  • the compound has the formula:
  • R 7 is 4-aminobut-1-yl. In some embodiments, R 7 is 3-aminoprop-1-yl.
  • the compound has the structure
  • B 1c is guanine.
  • B 2c is cytosine.
  • B 3c is thymine.
  • B 4c is guanine.
  • n 3 is 6.
  • p is 7.
  • R 3 is 4-aminobut-1-yl. In some embodiments, R 3 is 3-aminoprop-1-yl.
  • R 6 is 4-aminobut-1-yl. In some embodiments, R 6 is 3-aminoprop-1-yl.
  • R 7 is 4-aminobut-1-yl. In some embodiments, R 7 is 3-aminoprop-1-yl.
  • the compound comprises a sequence comprising G(CTG) 6 .
  • the compound has the structure
  • the compound has the structure
  • the compound has the structure
  • R 7 is 4-aminobut-1-yl. In some embodiments, R 7 is 3-aminoprop-1-yl.
  • the compound has the structure
  • B 1d is guanine.
  • B 2d is cytosine.
  • B 3d is thymine.
  • B 4d is guanine.
  • B 5d is cytosine.
  • B 6d is thymine.
  • B 7d is guanine.
  • B 8d is cytosine.
  • B 9d is thymine.
  • B 10d is guanine.
  • n 4 is 3. In some embodiments, n 5 is 2.
  • R 3 is 4-aminobut-1-yl. In some embodiments, at least one R 1 is 4-guanidinobut-1-yl. In some embodiments, each R 1 is 4-guanidinobut-1-yl.
  • R 3 is 4-aminobut-1-yl. In some embodiments, R 3 is 3-aminoprop-1-yl. In some embodiments,
  • R 7 is 4-aminobut-1-yl. In some embodiments, R 7 is 3-aminoprop-1-yl.
  • the compound has the structure:
  • the compound has the structure:
  • the compound has the structure:
  • B 2e is cytosine.
  • B 3e is thymine.
  • B 4e is guanine.
  • B 5e is cytosine.
  • B 6e is thymine.
  • B 7e is guanine.
  • B 8e is cytosine.
  • B 9e is thymine.
  • B 10e is guanine.
  • n 6 is 3. In some embodiments, n 7 is 2.
  • At least one R 2 is 3-guanidinoprop-1-yl. In some embodiments, each R 2 is 3-guanidinoprop-1-yl. In some embodiments, at least one R 2 is 4-guanidinobut-1-yl. In some embodiments, each R 2 is 4-guanidinobut-1-yl.
  • R 3 is 4-aminobut-1-yl. In some embodiments, R 3 is 3-aminoprop-1-yl.
  • R 7 is 4-aminobut-1-yl. In some embodiments, R 7 is 3-aminoprop-1-yl.
  • the compound has the structure:
  • the compound has the structure:
  • Each chemical group disclosed herein may be unsubstituted or substituted.
  • optional substituents include hydroxyl groups, sulfhydryl groups, halogens, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, hydrocarbyl groups, acyloxy groups, carbamate groups, amide groups, and ester groups.
  • Non-limiting examples of alkyl and alkylene groups include straight, branched, and cyclic alkyl and alkylene groups.
  • An alkyl group can be, for example, a C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 group that is substituted or un
  • Non-limiting examples of straight alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
  • Branched alkyl groups include any straight alkyl group substituted with any number of alkyl groups.
  • Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and t-butyl.
  • Non-limiting examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptlyl, and cyclooctyl groups. Cyclic alkyl groups also include fused-, bridged-, and spiro-bicycles and higher fused-, bridged-, and spiro-systems. A cyclic alkyl group can be substituted with any number of straight, branched, or cyclic alkyl groups.
  • Non-limiting examples of alkenyl and alkenylene groups include straight, branched, and cyclic alkenyl groups.
  • the olefin or olefins of an alkenyl group can be, for example, E, Z, cis, trans, terminal, or exo-methylene.
  • An alkenyl or alkenylene group can be, for example, a C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 group that is substituted or unsubstituted.
  • Non-limiting examples of alkynyl or alkynylene groups include straight, branched, and cyclic alkynyl groups.
  • the triple bond of an alkylnyl or alkynylene group can be internal or terminal.
  • An alkylnyl or alkynylene group can be, for example, a C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C
  • a halo-alkyl group can be any alkyl group substituted with any number of halogen atoms, for example, fluorine, chlorine, bromine, and iodine atoms.
  • a halo-alkenyl group can be any alkenyl group substituted with any number of halogen atoms.
  • a halo-alkynyl group can be any alkynyl group substituted with any number of halogen atoms.
  • An alkoxy group can be, for example, an oxygen atom substituted with any alkyl, alkenyl, or alkynyl group.
  • An ether or an ether group comprises an alkoxy group.
  • alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.
  • An aryl group can be heterocyclic or non-heterocyclic.
  • An aryl group can be monocyclic or polycyclic.
  • An aryl group can be substituted with any number of substituents described herein, for example, hydrocarbyl groups, alkyl groups, alkoxy groups, and halogen atoms.
  • Non-limiting examples of aryl groups include phenyl, toluyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thiophenyl, and furyl.
  • An aryloxy group can be, for example, an oxygen atom substituted with any aryl group, such as phenoxy.
  • An aralkyl group can be, for example, any alkyl group substituted with any aryl group, such as benzyl.
  • An arylalkoxy group can be, for example, an oxygen atom substituted with any aralkyl group, such as benzyloxy.
  • a heterocycle can be any ring containing a ring atom that is not carbon, for example, N, O, S, P, Si, B, or any other heteroatom.
  • a heterocycle can be substituted with any number of substituents, for example, alkyl groups and halogen atoms.
  • a heterocycle can be aromatic (heteroaryl) or non-aromatic.
  • Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine, succinamide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.
  • acyl group can be, for example, a carbonyl group substituted with hydrocarbyl, alkyl, hydrocarbyloxy, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, or a heterocycle.
  • Non-limiting examples of acyl include acetyl, benzoyl, benzyloxycarbonyl, phenoxycarbonyl, methoxycarbonyl, and ethoxycarbonyl.
  • An acyloxy group can be an oxygen atom substituted with an acyl group.
  • An ester or an ester group comprises an acyloxy group.
  • a non-limiting example of an acyloxy group, or an ester group, is acetate.
  • a carbamate group can be an oxygen atom substituted with a carbamoyl group, wherein the nitrogen atom of the carbamoyl group is unsubstituted, monosubstituted, or disubstituted with one or more of hydrocarbyl, alkyl, aryl, heterocyclyl, or aralkyl.
  • the nitrogen atom is disubstituted, the two substituents together with the nitrogen atom can form a heterocycle.
  • a hydrocarbyl group can be any group consisting of carbon and hydrogen atoms, and can include alkyl groups, alkenyl groups, alkynyl groups, and aryl groups.
  • a hydrocarbyl group can be, for example, a C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49
  • a hydrocarbylcarbonyl group can be a carbonyl group substituted with a hydrocarbyl group, which can be, for example, benzoyl, acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undencanoyl, dodecanoyl, tridencanoyl, myristoyl, pentadecenoyl, palmitoyl, heptadecanoyl, stearoyl, nondecanoyl, arachidoyl, as well as acyl groups derived from saturated, monounsaturated, and polyunsaturated fatty acids, such as myristoleoyl, palmitoleoyl, sapienoyl, oleoyl, elaidoyl, vaccenoyl, linole
  • a hydrocarbylcarbonyl group can be, for example, a C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 group.
  • An aminoalkylene group can be an alkyl group substituted with an amino group, such as, for example, aminomethyl, 2-aminoeth-1-yl, 3-aminoprop-1-yl, 2-aminoprop-1-yl, 4-aminobut-1-yl, 3-aminobut-1-yl, 2-aminobut-1-yl, 5-aminopen-1-yl, 4-aminopent-1-yl, 4-aminopent-1-yl, 3-aminopent-1-yl, 2-aminopent-1-yl, a lysine side chain, or an ornithine side chain.
  • amino group such as, for example, aminomethyl, 2-aminoeth-1-yl, 3-aminoprop-1-yl, 2-aminoprop-1-yl, 4-aminobut-1-yl, 3-aminobut-1-yl, 2-aminobut-1-yl, 5-aminopen-1-yl, 4-aminopent-1-yl, 4-amin
  • a guanidinoalkylene group can be an alkyl group substituted with a guanidino group, such as, for example, guanidinomethyl, 2-guanidinoeth-1-yl, 3-guanidinoprop-1-yl, 2-guanidinoprop-1-yl, 4-guanidinobut-1-yl, 3-guanidinobut-1-yl, 2-guanidinobut-1-yl, 5-guanidinopent-1-yl, 4-guanidinopent-1-yl, 4-guanidinopent-1-yl, 3-guanidinopent-1-yl, 2-guanidinopent-1-yl, an arginine side chain, or a homoarginine side chain
  • Polypeptide “peptide” and their grammatical equivalents as used herein refer to a polymer of amino acid residues.
  • Polypeptides and proteins disclosed herein can comprise synthetic amino acids in place of one or more naturally-occurring amino acids.
  • the disclosure contemplates both L- and D-forms of amino acid residues.
  • a compound of the disclosure may be radiolabeled.
  • One or more of the atoms of the compound of the disclosure may be substituted with a radioactive or non-radioactive isotope, for example of 2 H, 3 H, 11 C, 13 C, 14 C, 13N, 15 N, 15 O, 17 O, 18 O, or combinations thereof.
  • at least one carbon of the compound of the disclosure may be substituted with 14 C.
  • the present disclosure describes the use of a compound and methods to treat conditions or genetic disease, including trinucleotide repeat disorders.
  • the method can comprise administering to the subject a therapeutically-effective amount of a compound of the disclosure.
  • the genetic disease is a polyglutamine (polyQ) disease.
  • Polyglutamine diseases include trinucleotide repeat disorders involving genes that comprise an abnormally high number of CAG repeats.
  • the polyglutamine disease is SCAT (Spinocerebellar ataxia Type 1), SCA2 (Spinocerebellar ataxia Type 2), SCA3 (Spinocerebellar ataxia Type 3 or Machado-Joseph disease), SCA6 (Spinocerebellar ataxia Type 6), SCAT (Spinocerebellar ataxia Type 7), SCA12 (Spinocerebellar ataxia Type 12), SCA17 (Spinocerebellar ataxia Type 17), DRPLA (Dentatorubropallidoluysian atrophy), SBMA (Spinal and bulbar muscular atrophy), or Huntington's disease.
  • SCAT Spinocerebellar ataxia Type 1
  • SCA2 Spinocerebellar ataxia Type 2
  • SCA3 Spinocerebellar ataxia Type 3 or Machado-Joseph disease
  • SCA6 Spinocerebellar ataxia Type 6
  • the condition is a neurological condition.
  • the neurological condition is Huntington's disease.
  • the condition is a central nervous system condition.
  • the condition is associated with aging.
  • the condition is associated with cognitive impairment.
  • the condition is associated with memory loss.
  • the condition is associated with deterioration of motor skills.
  • the polyglutamine disease is Huntington's disease.
  • Treatment can be administered on the basis of number of CAG repeats in the HTT gene of a subject.
  • a subject administered a compound of the disclosure can comprise a HTT gene that contains more than 27 CAG repeats.
  • the HTT gene of the subject contains at least 36 repeats, at least 40 repeats, at least 50 repeats, or at least 60 repeats.
  • the HTT gene of the subject contains from 27 to 36 repeats, from 27 to 36 repeats, from 27 to 40 repeats, from 27 to 60 repeats, from 27 to 80 repeats, from 27 to 90 repeats, from 36 to 40 repeats, from 36 to 60 repeats, from 36 to 80 repeats, from 36 to 90 repeats, from 40 to 60 repeats, from 40 to 80 repeats, from 40 to 90 repeats, or from 60 to 90 repeats.
  • administration of a compound of the disclosure does not exhibit immunogenicity. In some embodiments, administration of a compound of the disclosure does not promote generation of neutralizing antibodies, complement factors, pro-inflammatory cytokines, or type 1 interferons upon or after administration of the compound to a subject. In some embodiments, the compounds do not activate the TLR9 receptor and are not presented in MHCI or MHCII complexes to the immune system.
  • Compounds of the disclosure can be systemically administered to a subject in need thereof as a therapeutically-effective amount of a compound that binds to a repeat codon.
  • the subject can comprise a bloodstream, a brain, and a blood-brain-barrier.
  • the compound that binds to the repeat codon can enter the brain by passing from the bloodstream through the blood-brain-barrier into the brain.
  • a compound of the disclosure or a composition comprising a compound of the disclosure can be administered to a subject in various forms and by various suitable routes of administration.
  • a compound of the disclosure or a composition comprising a compound of the disclosure can be administered in a local manner, for example, via injection of the compound directly into an organ, optionally in a depot or sustained release formulation or implant.
  • a compound of the disclosure or a composition comprising a compound of the disclosure can be administered in a systemic manner.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered parenterally.
  • Parenteral administration can be, for example, by bolus injection or by gradual infusion or perfusion over time. Administration can also be by surgical deposition of a bolus, or positioning of a medical device.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered orally.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by an intravenous, intratumoral, subcutaneous, intramuscular, intracerebral, intracerebroventricular, intra-articular, intraperitoneal, intracranial, intrathecal, intranasal, buccal, sublingual, oral, or rectal administration route.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by intravenous administration.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by subcutaneous administration.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by intracerebroventricular administration.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by oral administration.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by intrathecal administration.
  • any aforementioned route of administration can be combined with another route of administration.
  • a compound of the disclosure can be delivered by a first route of administration, and one or more subsequent maintenance doses of the compound can be delivered by the same or a different route of administration.
  • a compound of the disclosure or a composition comprising a compound of the disclosure is administered by intrathecal administration, and one or more subsequent maintenance doses of the compound or the composition comprising the compound are delivered by subcutaneous administration or intravenous administration.
  • Non-limiting examples of suitable modes and routes of administration include oral, topical, parenteral, intravenous injection, intravenous infusion, subcutaneous injection, subcutaneous infusion, intramuscular injection, intramuscular infusion, intradermal injection, intradermal infusion, intraperitoneal injection, intraperitoneal infusion, intracerebral injection, intracerebral infusion, subarachnoid injection, subarachnoid infusion, intraocular injection, intraspinal injection, intrasternal injection, ophthalmic administration, endothelial administration, local administration, intranasal administration, intrapulmonary administration, rectal administration, intraarterial administration, intrathecal administration, inhalation, intralesional administration, intradermal administration, epidural administration, absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa), intracapsular administration, subcapsular administration, intracardiac administration, transtracheal administration, subcuticular administration, subarachnoid administration, sub
  • a compound of the disclosure or a composition comprising a compound of the disclosure can be administered via a non-invasive method.
  • non-invasive modes of administering can include using a needleless injection device, and topical administration, for example, eye drops. Multiple administration routes can be employed for efficient delivery.
  • the compositions can be in the form of solid, semi solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, or gels, for example, in unit dosage form suitable for single administration of a precise dosage.
  • the composition can be formulated into any suitable dosage form for administration, for example, aqueous dispersions, liquids, gels, syrups, elixirs, slurries, and suspensions, for administration to a subject or a patient.
  • Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets.
  • Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein.
  • Semi-solid compositions include, for example, gels, suspensions and creams. The compositions can be in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
  • the composition is formulated into solutions (for example, for IV administration).
  • the pharmaceutical composition is formulated as an infusion.
  • the pharmaceutical composition is formulated as an injection.
  • a compound of the disclosure or a composition comprising a compound of the disclosure can be administered in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation.
  • a rapid release form can provide an immediate release.
  • An extended release formulation can provide a controlled release or a sustained delayed release.
  • a composition comprising a compound of the disclosure can be, for example, an immediate release form or a controlled release formulation.
  • An immediate release formulation can be formulated to allow the compounds to act rapidly.
  • Non-limiting examples of immediate release formulations include readily dissolvable formulations.
  • a controlled release formulation can be a pharmaceutical formulation that has been adapted such that release rates and release profiles of the active agent can be matched to physiological and chronotherapeutic requirements, or has been formulated to effect release of an active agent at a programmed rate.
  • Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., of synthetic or natural origin), other gelling agents (e.g., gel-forming dietary fibers), matrix-based formulations (e.g., formulations comprising a polymeric material having at least one active ingredient dispersed through), granules within a matrix, polymeric mixtures, and granular masses.
  • hydrogels e.g., of synthetic or natural origin
  • other gelling agents e.g., gel-forming dietary fibers
  • matrix-based formulations e.g., formulations comprising a polymeric material having at least one active ingredient dispersed through
  • a controlled release formulation is a delayed release form.
  • a delayed release form can be formulated to delay a compound's action for an extended period of time.
  • a delayed release form can be formulated to delay the release of an effective dose of one or more compounds, for example, for about 4, about 8, about 12, about 16, or about 24 hours.
  • a controlled release formulation can be a sustained release form.
  • a sustained release form can be formulated to sustain, for example, the compound's action over an extended period of time.
  • a sustained release form can be formulated to provide an effective dose of any compound described herein (e.g., provide a physiologically-effective blood profile) over about 4, about 8, about 12, about 16, or about 24 hours.
  • a pharmaceutical composition disclosed herein can be targeted to any suitable tissue or cell type. Modes, routes, and compositions of the disclosure can be suitable to target a compound of the disclosure to a particular tissue, or a subset of tissues.
  • tissues that can be targeted include kidney (e.g., kidney cortex), joints, cartilage, liver, salivary glands, bone (e.g., bone surface), skin, lung, muscle, pancreas, hair follicles, large intestine mucosa, aortic wall, small intestine mucosa, adrenal gland, stomach mucosa, spleen, bone marrow, lymph nodes, thymus, brain, cerebellum, olfactory bulb, thalamus, caudate putamen, cerebral cortex, substantia nigra, lateral ventricle, choroid plexus, and combinations thereof
  • compositions described herein can be in unit dosage forms suitable for single administration of precise dosages.
  • the formulation is divided into unit doses containing appropriate quantities of one or more compound.
  • the dosage e.g., therapeutically-effective amount
  • for a compound described herein can be in any amount necessary.
  • a compound described herein can be present in a composition or a unit dose in a range of from about 1 mg to about 2000 mg; from about 5 mg to about 1000 mg, from about 10 mg to about 25 mg, from about 50 mg to about 250 mg, from about 100 mg to about 200 mg, from about 1 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, from about 500 mg to about 550 mg, from about 550 mg to about 600 mg, from about 600 mg to about 650 mg, from about 650 mg to about 700 mg, from about 700 mg to about 750 mg, from about 750 mg to about 800 mg, from about 800 mg to about 850 mg, from about 850 mg to about 900 mg, from about 900 mg to about 950 mg, or from about
  • a compound described herein can be present in a composition or a unit dose in a range of from about 1 ⁇ g to about 2000 ⁇ g; from about 5 ⁇ g to about 1000 ⁇ g, from about 10 ⁇ g to about 25 ⁇ g, from about 50 ⁇ g to about 250 ⁇ g, from about 100 ⁇ g to about 200 ⁇ g, from about 1 ⁇ g to about 50 ⁇ g, from about 50 ⁇ g to about 100 ⁇ g, from about 100 ⁇ g to about 150 ⁇ g, from about 150 ⁇ g to about 200 ⁇ g, from about 200 ⁇ g to about 250 ⁇ g, from about 250 ⁇ g to about 300 ⁇ g, from about 300 ⁇ g to about 350 ⁇ g, from about 350 ⁇ g to about 400 ⁇ g, from about 400 ⁇ g to about 450 ⁇ g, from about 450 ⁇ g to about 500 ⁇ g, from about 500 ⁇ g to about 550 ⁇ g, from about 550 ⁇ g to about 600 ⁇ g, from about 600 ⁇ g to
  • a compound described herein can be present in a composition or a unit dose in an amount of about 0.001 mg, about 0.002 mg, about 0.003 mg, about 0.004 mg, about 0.005 mg, about 0.006 mg, about 0.007 mg, about 0.008 mg, about 0.009 mg, about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about
  • a composition is present in a composition or a unit dose in an amount that is at least about 0.001 mg, at least about 0.002 mg, at least about 0.003 mg, at least about 0.004 mg, at least about 0.005 mg, at least about 0.006 mg, at least about 0.007 mg, at least about 0.008 mg, at least about 0.009 mg, at least about 0.01 mg, at least about 0.02 mg, at least about 0.03 mg, at least about 0.04 mg, at least about 0.05 mg, at least about 0.06 mg, at least about 0.07 mg, at least about 0.08 mg, at least about 0.09 mg, at least about 0.1 mg, at least about 0.2 mg, at least about 0.3 mg, at least about 0.4 mg, at least about 0.5 mg, at least about 0.6 mg, at least about 0.7 mg, at least about 0.8 mg, at least about 0.9 mg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about
  • a composition is present in a composition or a unit dose in an amount that is at most about 0.001 mg, at most about 0.002 mg, at most about 0.003 mg, at most about 0.004 mg, at most about 0.005 mg, at most about 0.006 mg, at most about 0.007 mg, at most about 0.008 mg, at most about 0.009 mg, at most about 0.01 mg, at most about 0.02 mg, at most about 0.03 mg, at most about 0.04 mg, at most about 0.05 mg, at most about 0.06 mg, at most about 0.07 mg, at most about 0.08 mg, at most about 0.09 mg, at most about 0.1 mg, at most about 0.2 mg, at most about 0.3 mg, at most about 0.4 mg, at most about 0.5 mg, at most about 0.6 mg, at most about 0.7 mg, at most about 0.8 mg, at most about 0.9 mg, at most about 1 mg, at most about 2 mg, at most about 3 mg, at most about 4 mg, at most about 5 mg, at most about
  • a dose (e.g., a unit dose) is about 0.001 mg/kg, about 0.002 mg/kg, about 0.003 mg/kg, about 0.004 mg/kg, about 0.005 mg/kg, about 0.006 mg/kg, about 0.007 mg/kg, about 0.008 mg/kg, about 0.009 mg/kg, about 0.01 mg/kg, about 0.02 mg/kg, about 0.03 mg/kg, about 0.04 mg/kg, about 0.05 mg/kg, about 0.06 mg/kg, about 0.07 mg/kg, about 0.08 mg/kg, about 0.09 mg/kg, about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 10 mg/kg, about
  • a dose is at least about 0.001 mg/kg, at least about 0.002 mg/kg, at least about 0.003 mg/kg, at least about 0.004 mg/kg, at least about 0.005 mg/kg, at least about 0.006 mg/kg, at least about 0.007 mg/kg, at least about 0.008 mg/kg, at least about 0.009 mg/kg, at least about 0.01 mg/kg, at least about 0.02 mg/kg, at least about 0.03 mg/kg, at least about 0.04 mg/kg, at least about 0.05 mg/kg, at least about 0.06 mg/kg, at least about 0.07 mg/kg, at least about 0.08 mg/kg, at least about 0.09 mg/kg, at least about 0.1 mg/kg, at least about 0.2 mg/kg, at least about 0.3 mg/kg, at least about 0.4 mg/kg, at least about 0.5 mg/kg, at least about 0.6 mg/kg, at least about 0.7 mg/kg, at
  • a dose (e.g., a unit dose) is at most about 0.001 mg/kg, at most about 0.002 mg/kg, at most about 0.003 mg/kg, at most about 0.004 mg/kg, at most about 0.005 mg/kg, at most about 0.006 mg/kg, at most about 0.007 mg/kg, at most about 0.008 mg/kg, at most about 0.009 mg/kg, at most about 0.01 mg/kg, at most about 0.02 mg/kg, at most about 0.03 mg/kg, at most about 0.04 mg/kg, at most about 0.05 mg/kg, at most about 0.06 mg/kg, at most about 0.07 mg/kg, at most about 0.08 mg/kg, at most about 0.09 mg/kg, at most about 0.1 mg/kg, at most about 0.2 mg/kg, at most about 0.3 mg/kg, at most about 0.4 mg/kg, at most about 0.5 mg/kg, at most about 0.6 mg/kg, at most about 0.7 mg/kg, at
  • a dose is about 1 mg/kg to about 2000 mg/kg; from about 5 mg/kg to about 1000 mg/kg, from about 10 mg/kg to about 25 mg/kg, from about 50 mg/kg to about 250 mg/kg, from about 100 mg/kg to about 200 mg/kg, from about 1 mg/kg to about 50 mg/kg, from about 50 mg/kg to about 100 mg/kg, from about 100 mg/kg to about 150 mg/kg, from about 150 mg/kg to about 200 mg/kg, from about 200 mg/kg to about 250 mg/kg, from about 250 mg/kg to about 300 mg/kg, from about 300 mg/kg to about 350 mg/kg, from about 350 mg/kg to about 400 mg/kg, from about 400 mg/kg to about 450 mg/kg, from about 450 mg/kg to about 500 mg/kg, from about 500 mg/kg to about 550 mg/kg, from about 550 mg/kg to about 600 mg/kg, from about 600 mg/kg to about 650 mg
  • compositions and formulations described herein can comprise, for example, a compound of the disclosure at any suitable concentration.
  • a formulation can comprise a composition of the disclosure at a concentration of, for example, about 0.001 mg/mL, about 0.002 mg/mL, about 0.003 mg/mL, about 0.004 mg/mL, about 0.005 mg/mL, about 0.006 mg/mL, about 0.007 mg/mL, about 0.008 mg/mL, about 0.009 mg/mL, about 0.01 mg/mL, about 0.02 mg/mL, about 0.03 mg/mL, about 0.04 mg/mL, about 0.05 mg/mL, about 0.06 mg/mL, about 0.07 mg/mL, about 0.08 mg/mL, about 0.09 mg/mL, about 0.1 mg/mL, about 0.2 mg/mL, about 0.3 mg/mL, about 0.4 mg/mL, about 0.5 mg/mL, about 0.6 mg/mL, about 0.7 mg/mL
  • a formulation of the disclosure comprises a compound of the disclosure at a concentration of at least about 0.001 mg/mL, at least about 0.002 mg/mL, at least about 0.003 mg/mL, at least about 0.004 mg/mL, at least about 0.005 mg/mL, at least about 0.006 mg/mL, at least about 0.007 mg/mL, at least about 0.008 mg/mL, at least about 0.009 mg/mL, at least about 0.01 mg/mL, at least about 0.02 mg/mL, at least about 0.03 mg/mL, at least about 0.04 mg/mL, at least about 0.05 mg/mL, at least about 0.06 mg/mL, at least about 0.07 mg/mL, at least about 0.08 mg/mL, at least about 0.09 mg/mL, at least about 0.1 mg/mL, at least about 0.2 mg/mL, at least about 0.3 mg/mL, at least about 0.4 mg/mL, at least about
  • a formulation of the disclosure comprises a compound of the disclosure at a concentration of at most about 0.002 mg/mL, at most about 0.003 mg/mL, at most about 0.004 mg/mL, at most about 0.005 mg/mL, at most about 0.006 mg/mL, at most about 0.007 mg/mL, at most about 0.008 mg/mL, at most about 0.009 mg/mL, at most about 0.01 mg/mL, at most about 0.02 mg/mL, at most about 0.03 mg/mL, at most about 0.04 mg/mL, at most about 0.05 mg/mL, at most about 0.06 mg/mL, at most about 0.07 mg/mL, at most about 0.08 mg/mL, at most about 0.09 mg/mL, at most about 0.1 mg/mL, at most about 0.2 mg/mL, at most about 0.3 mg/mL, at most about 0.4 mg/mL, at most about 0.5 mg/mL, at most about 0.1 mg/m
  • a formulation of the disclosure comprises a compound of the disclosure at a concentration of about 1 mg/mL to about 2000 mg/mL; from about 5 mg/mL to about 1000 mg/mL, from about 10 mg/mL to about 25 mg/mL, from about 50 mg/mL to about 250 mg/mL, from about 100 mg/mL to about 200 mg/mL, from about 1 mg/mL to about 50 mg/mL, from about 50 mg/mL to about 100 mg/mL, from about 100 mg/mL to about 150 mg/mL, from about 150 mg/mL to about 200 mg/mL, from about 200 mg/mL to about 250 mg/mL, from about 250 mg/mL to about 300 mg/mL, from about 300 mg/mL to about 350 mg/mL, from about 350 mg/mL to about 400 mg/mL, from about 400 mg/mL to about 450 mg/mL, from about 450 mg/mL to about 500 mg/mL, from about 500 mg/mL
  • Compounds disclosed herein can have favorable properties for administration to subjects or patients, for example, favorable pharmacokinetic or tissue distribution parameters.
  • a study or assay e.g., tissue distribution study
  • the study or assay comprises administering (e.g., intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.1 mg/kg to about 1.5 mg/kg, then the compound accumulates in the study patient's brain for at most about 1 month after dosing.
  • the compound is not observed or is rarely observed at a detectable level during the month in the study patient's plasma, intestine, liver, lung, kidney, and/or muscle.
  • the compound can be subjected to an assay or a study (e.g., a tissue distribution study) and in the study, the compound can be observed to accumulate in the brain of a study patient (e.g., mice) for a time period (e.g., most about a month) after the administering. In some embodiments, the compound is not observed at a detectable level during the time period in the plasma, intestine, liver, lung, kidney, and/or muscle of the study patient.
  • the assay can comprise administering (e.g., intracerebroventricular administration) a dose amount (e.g., about 0.1 mg/kg to about 1.5 mg/kg) of the compound to a study patient (e.g., mice).
  • Blood samples can be collected (e.g., from cava veins) of the study patient at a time point (e.g., between about 1 hour and 28 days) post administration. After collecting the blood samples, the study patients can be euthanized at a time point between (e.g., about 1 hour and 28 days) post administration. After the euthanasia, various tissues (e.g., brain, intestine, liver, lung, kidney, and/or muscle tissues) can be collected from the study patients.
  • various tissues e.g., brain, intestine, liver, lung, kidney, and/or muscle tissues
  • Various analytical techniques can be used to determine concentrations of the compound in tissues and/or other samples collected from study patients (for example, blood, plasma, urine, feces, etc).
  • mass spectrometry for example, liquid chromatography mass spectrometry (LC-MS), gas chromatography mass spectrometry (GC-MS), tandem MS (MS/MS, e.g, LC-MS/MS or GC-MS/MS), Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), triple quadrupole mass spectrometry (TQMS), Quadrupole Trap MS, hybrid linear trap orbitrap MS, quadrupole-Orbitrap mass spectrometry, High performance or ultra-high performance liquid chromatography (HPLC or UHPLC, e.g., with MS or ultraviolet detection), time of flight (TOF) MS, Selected reaction monitoring (SRM), Multiple reaction monitoring (MRM) nuclear
  • LC-MS liquid chromatography mass spectrometry
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient (e.g., mouse) or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the compound accumulates in the study patient's or subject's brain for a time period of at most about 1 month (for example, at most about 3 days, at most about 7 days, at most about 14 days, at most about 21 days, at most about 27 days, or at most about 28 days) after dosing.
  • the compound is not observed or is rarely observed during this time period at a detectable level in the study patient
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the compound accumulates in the study patient's or subject's brain for a time period of at least about 1 day (for example, at least about 1 day, at least about 3 days, at least about 7 days, at least about 14 days, at least about 21 days, at least about 27 days, at least about 28 days, at least about 1 month, at least about 2 months, or at least about 3 months) after dosing.
  • the compound is not observed or is
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the compound accumulates in the study patient's or subject's spleen for a time period of at most about 1 month (for example, at most about 3 days, at most about 7 days, at most about 14 days, at most about 21 days, at most about 27 days, or at most about 28 days) after dosing.
  • the compound is not observed or is rarely observed at a detectable level during this time period in the study patient's or subject'
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the compound accumulates in the study patient's or subject's spleen for a time period of at least about 1 day (for example, at least about 1 day, at least about 3 days, at least about 7 days, at least about 14 days, at least about 21 days, at least about 27 days, at least about 28 days, at least about 1 month, at least about 2 months, or at least about 3 months) after dosing.
  • the compound is not
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the compound accumulates in the study patient's or subject's heart for a timer period of at most about 1 month (for example, at most about 3 days, at most about 7 days, at most about 14 days, at most about 21 days, at most about 27 days, or at most about 28 days) after dosing.
  • the compound is not observed or is rarely observed at a detectable level during this time period in the study patient's or subject's plasma
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the compound accumulates in the study patient's or subject's heart for a time period of at least about 1 day (for example, at least about 1 day, at least about 3 days, at least about 7 days, at least about 14 days, at least about 21 days, at least about 27 days, at least about 28 days, at least about 1 month, at least about 2 months, or at least about 3 months) after dosing.
  • the compound is not observed or is
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the compound accumulates in the study patient's or subject's brain for a time period of at most about 1 month (for example, at most about 3 days, at most about 7 days, at most about 14 days, at most about 21 days, at most about 27 days, or at most about 28 days) after dosing.
  • the compound is not observed or is rarely observed at a detectable level during this time period
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the compound accumulates in the study patient's or subject's brain at a time period for at least about 1 day (for example, at least about 1 day, at least about 3 days, at least about 7 days, at least about 14 days, at least about 21 days, at least about 27 days, at least about 28 days, at least about 1 month, at least about 2 months, or at least about 3 months) after dosing.
  • a compound of the disclosure e.g., Compound
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the compound accumulates in the study patient's or subject's spleen for a time period of at most about 1 month (for example, at most about 3 days, at most about 7 days, at most about 14 days, at most about 21 days, at most about 27 days, or at most about 28 days) after dosing.
  • the compound is not observed or is rarely observed during this time period at a
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the compound accumulates in the study patient's or subject's spleen for a time period of at least about 1 day (for example, at least about 1 day, at least about 3 days, at least about 7 days, at least about 14 days, at least about 21 days, at least about 27 days, at least about 28 days, at least about 1 month, at least about 2 months, or at least about 3 months) after do
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the compound accumulates in the study patient's or subject's heart for a time period of at most about 1 month (for example, at most about 3 days, at most about 7 days, at most about 14 days, at most about 21 days, at most about 27 days, or at most about 28 days) after dosing.
  • the compound is not observed or is rarely observed at a detectable level during this time period
  • an assay or study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure (e.g., Compound 1) to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the compound accumulates in the study patient's or subject's heart for a time period of at least about 1 day (for example, at least about 1 day, at least about 3 days, at least about 7 days, at least about 14 days, at least about 21 days, at least about 27 days, at least about 28 days, at least about 1 month, at least about 2 months, or at least about 3 months) after dosing.
  • a compound of the disclosure e.g., Compound
  • a dose can be modulated to achieve a desired pharmacokinetic or pharmacodynamics profile, such as a desired or effective blood profile, as described herein.
  • Pharmacokinetic and pharmacodynamic data can be obtained by various experimental techniques. Appropriate pharmacokinetic and pharmacodynamic profile components describing a particular composition can vary due to variations in drug metabolism in human subjects. Pharmacokinetic and pharmacodynamic profiles can be based on the determination of the mean parameters of a group of subjects. The group of subjects includes any reasonable number of subjects suitable for determining a representative mean, e.g., 5 subjects, 10 subjects, 15 subjects, 20 subjects, 25 subjects, 30 subjects, 35 subjects, or more. The mean is determined, for example, by calculating the average of all subject's measurements for each parameter measured. A dose can be modulated to achieve a desired pharmacokinetic or pharmacodynamics profile, such as a desired or effective blood profile, as described herein.
  • the subject is a vertebrate. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a primate, ape, monkey, sheep, equine, bovine, porcine, minipig, canine, feline, goat, camelid, rodent, rabbit, mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, guinea pig, C57BL6J mouse, Beagle dog, Gottingen minipig, or Cynomolgus monkey. In some embodiments, a subject is a non-human subject. In some embodiments, a subject is a veterinary subject.
  • the patient is a vertebrate. In some embodiments, the patient is a mammal. In some embodiments, the patient is a human. In some embodiments, the patient is a primate, ape, monkey, sheep, equine, bovine, porcine, minipig, canine, feline, goat, camelid, rodent, rabbit, mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, guinea pig, C57BL6J mouse, Beagle dog, Gottingen minipig, or Cynomolgus monkey. In some embodiments, a patient is a non-human patient. In some embodiments, a patient is a veterinary patient.
  • a patient and a subject are the same species. In some embodiments, a subject and a patient are human.
  • a patient and a subject are different species.
  • a subject is human and a patient is a non-human, for example, a non-human vertebrate, non-human mammal, non-human primate, ape, monkey, sheep, equine, bovine, porcine, minipig, canine, feline, goat, camelid, rodent, rabbit, mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, or guinea pig.
  • a patient is human and a subject is a non-human, for example, a non-human vertebrate, non-human mammal, non-human primate, ape, monkey, sheep, equine, bovine, porcine, minipig, canine, feline, goat, camelid, rodent, rabbit, mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, or guinea pig.
  • a non-human vertebrate for example, a non-human vertebrate, non-human mammal, non-human primate, ape, monkey, sheep, equine, bovine, porcine, minipig, canine, feline, goat, camelid, rodent, rabbit, mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, or guinea pig.
  • a pharmacokinetic parameter can be any parameter suitable for describing a compound.
  • Non-limiting examples of pharmacodynamic and pharmacokinetic parameters that can be calculated for a compound that is administered with the methods of the invention include:
  • k the peak plasma concentration of a drug after administration, C max ; l) the time taken by a drug to reach C max ; t max ; m) the lowest concentration that a drug reaches before the next dose is administered C min ; and n) the peak trough fluctuation within one dosing interval at steady state, which can be represented as
  • a mean maximum brain concentration e.g., 3000 ng/mL to about 22000 ng/mL
  • a study patient e.g., mice
  • a time to maximum brain concentration e.g., about 1 hour to about 50 hours post administration
  • the assay can comprise administering by administering (e.g., intracerebroventricular administration) a dose amount of about 0.1 mg/kg to about 2 mg/kg of the compound to the study patient (e.g., mice).
  • mice can be euthanized at a time point (e.g., between about 1 hour and 28 days) post administration.
  • Various tissues e.g., brain tissues
  • Concentrations of the tissues in the study patients can be determined using various techniques, disclosed herein, such as liquid chromatography-tandem mass spectrometry.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in brain is at least 0.5, at least 1, at least 2, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, or at least 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in brain is at most 6, at most 12, at most 16, at most 20, at most 24, at most 28, at most 32, at most 36, at most 40, at most 44, at most 48, at most 72, at most 96, or at most 120 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in brain is about 0.5 to about 120, about 1 to about 24, about 1 to about 36, about 1 to about 48, about 2 to about 36, about 6 to about 24, about 1 to about 6, about 6 to about 12, about 12 to about 24, about 12 to about 18, about 18 to about 48, about 18 to about 36, or about 24 to about 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean C max of the compound in brain is at least about 1, at least about 1000, at least about 2000, at least about 3000, at least about 4000, at least about 5000, at least about 6000, at least about 7000, at least about 8000, at least about 9000, at least about 10000, at least about 12000, at least about 14000, at least about 16000, at least about 18000, at least about 20000, at least about 22000, or at least about 25000
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Cmax of the compound in brain is at most about 3000, at most about 4000, at most about 5000, at most about 6000, at most about 7000, at most about 8000, at most about 9000, at most about 10000, at most about 12000, at most about 14000, at most about 16000, at most about 18000, at most about 20000, at most about 22000, at most about 25000, at most about 30000 or at most about 50000 ng/
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Cmax of the compound in brain is about 1000 to about 50000, about 2000 to about 25000, about 3000 to about 22000, about 2000 to about 5000, about 5000 to about 15000, or about 10000 to about 25000 ng/mL.
  • the mean maximum brain concentration is from about 3000 ng/mL to about 4000 ng/mL. In some embodiments, at a dose amount of 0.6 mg/kg, the mean maximum brain concentration is from about 6000 ng/mL to about 12000 ng/mL. In some embodiments, at a dose amount of 1 mg/kg, the mean maximum brain concentration is from about 15000 ng/mL to about 22000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for brain is at least about 0.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 1.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 2.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 4 ⁇ 10
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for brain is at most about 1.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 2.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 4 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 6 ⁇ 10 ⁇
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for brain is about 0.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 20 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 15 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 10 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 1.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for brain is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 10, at least about 12, at least about 14, at least about 21, at least about 28, at least about 35, at least about 42, at least about 49, or at least about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for brain is at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, at most about 6, at most about 7, at most about 10, at most about 12, at most about 14, at most about 21, at most about 28, at most about 35, at most about 42, at most about 49, at most about 100 days, at most about 200, or at most about 300 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for brain is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80 to about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T 1/2 for brain is at least 6, at least 24, at least 48, at least 100, at least 200, at least 500, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, or at least 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T1 ⁇ 2 for brain is at most 24, at most 48, at most 100, at most 200, at most 500, at most 1000, at most 1500, at most 2000, at most 2500, at most 3000, at most 5000, at most 10000, or at most 20000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T1 ⁇ 2 for brain is about 24 to about 20000, about 100 to about 15000, about 500 to about 10000, about 500 to about 5000, about 100 to about 1000, about 1000 to about 2000, or about 3000 to about 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in brain is at least 0.5, at least 1, at least 2, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, or at least 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in brain is at most 6, at most 12, at most 16, at most 20, at most 24, at most 28, at most 32, at most 36, at most 40, at most 44, at most 48, at most 72, at most 96, or at most 120 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in brain is about 0.5 to about 120, about 1 to about 24, about 1 to about 36, about 1 to about 48, about 2 to about 36, about 6 to about 24, about 1 to about 6, about 6 to about 12, about 12 to about 24, about 12 to about 18, about 18 to about 48, about 18 to about 36, or about 24 to about 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean C max of the compound in brain is at least about 1, at least about 1000, at least about 2000, at least about 3000, at least about 4000, at least about 5000, at least about 6000, at least about 7000, at least about 8000, at least about 9000, at least about 10000, at least about 12000, at least about 14000, at least about 16000, at least about 18000, at least about 20000,
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean C max of the compound in brain is at most about 3000, at most about 4000, at most about 5000, at most about 6000, at most about 7000, at most about 8000, at most about 9000, at most about 10000, at most about 12000, at most about 14000, at most about 16000, at most about 18000, at most about 20000, at most about 22000, at most about 25000, at most
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Cmax of the compound in brain is about 1000 to about 50000, about 2000 to about 25000, about 3000 to about 22000, about 2000 to about 5000, about 5000 to about 15000, or about 10000 to about 25000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for brain is at least about 0.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 1.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 2.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 3 ⁇ 10 ⁇ circumflex
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for brain is at most about 1.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 2.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 4 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 5 ⁇ 10 ⁇ circumflex over
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for brain is about 0.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 20 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 15 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 10 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 1.5 ⁇
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for brain is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 10, at least about 12, at least about 14, at least about 21, at least about 28, at least about 35, at least about 42, at least about 49, or at least about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for brain is at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, at most about 6, at most about 7, at most about 10, at most about 12, at most about 14, at most about 21, at most about 28, at most about 35, at most about 42, at most about 49, at most about 100 days, at most about 200, or at most about 300 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for brain is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80 to about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for brain is at least 6, at least 24, at least 48, at least 100, at least 200, at least 500, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, or at least 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for brain is at most 24, at most 48, at most 100, at most 200, at most 500, at most 1000, at most 1500, at most 2000, at most 2500, at most 3000, at most 5000, at most 10000, or at most 20000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for brain is about 24 to about 20000, about 100 to about 15000, about 500 to about 10000, about 500 to about 5000, about 100 to about 1000, about 1000 to about 2000, or about 3000 to about 5000 hours.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 1.5 hour at 0.3 mg/kg, after administration of a single dose to a male subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 48 hour at 0.3 mg/kg, after administration of a single dose to a female subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 4 hour at 0.6 mg/kg, after administration of a single dose to a male subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 1.5 hour at 0.6 mg/kg, after administration of a single dose to a female subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 24 hour at 1 mg/kg, after administration of a single dose to a male subject.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in spleen is at least 0.5, at least 1, at least 2, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, or at least 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in spleen is at most 6, at most 12, at most 16, at most 20, at most 24, at most 28, at most 32, at most 36, at most 40, at most 44, at most 48, at most 72, at most 96, or at most 120 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in spleen is about 0.5 to about 120, about 1 to about 24, about 1 to about 36, about 1 to about 48, about 2 to about 36, about 6 to about 24, about 1 to about 6, about 6 to about 12, about 12 to about 24, about 12 to about 18, about 18 to about 48, about 18 to about 36, or about 24 to about 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean C max of the compound in spleen is at least about 1, at least about 50, at least about 100, at least about 250, at least about 500, at least about 750, at least about 1250, at least about 1500, at least about 2000, at least about 2500, at least about 3000, at least about 5000, or at least about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean C max of the compound in spleen is at most about 1000, at most about 1500, at most about 2000, at most about 2500, at most about 3000, at most about 4000, at most about 5000, or at most about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean C max of the compound in spleen is about 100 to about 50000, about 200 to about 5000, about 300 to about 4000, about 500 to about 3000, about 500 to about 1000, about 1000 to about 2000, about 1000 to about 3000, or about 2000 to about 4000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for spleen is at least about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.3 ⁇ 10 ⁇ circumflex over ( )
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for spleen is at most about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.4 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.5 ⁇ 10 ⁇ circumflex over ( )
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for spleen is about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.075 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.09 ⁇ 10 ⁇ circumflex
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for spleen is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 10, at least about 12, at least about 14, at least about 21, at least about 28, at least about 35, at least about 42, at least about 49, or at least about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for spleen is at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, at most about 6, at most about 7, at most about 10, at most about 12, at most about 14, at most about 21, at most about 28, at most about 35, at most about 42, at most about 49, at most about 100 days, at most about 200, or at most about 300 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for spleen is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80 to about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T 1/2 for spleen is at least 6, at least 24, at least 48, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T1 ⁇ 2 for spleen is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T1 ⁇ 2 for spleen is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in spleen is at least 0.5, at least 1, at least 2, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, or at least 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in spleen is at most 6, at most 12, at most 16, at most 20, at most 24, at most 28, at most 32, at most 36, at most 40, at most 44, at most 48, at most 72, at most 96, or at most 120 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in spleen is about 0.5 to about 120, about 1 to about 24, about 1 to about 36, about 1 to about 48, about 2 to about 36, about 6 to about 24, about 1 to about 6, about 6 to about 12, about 12 to about 24, about 12 to about 18, about 18 to about 48, about 18 to about 36, or about 24 to about 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean C max of the compound in spleen is at least about 1, at least about 50, at least about 100, at least about 250, at least about 500, at least about 750, at least about 1250, at least about 1500, at least about 2000, at least about 2500, at least about 3000, at least about 5000, or at least about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Cmax of the compound in spleen is at most about 1000, at most about 1500, at most about 2000, at most about 2500, at most about 3000, at most about 4000, at most about 5000, or at most about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Cmax of the compound in spleen is about 100 to about 50000, about 200 to about 5000, about 300 to about 4000, about 500 to about 3000, about 500 to about 1000, about 1000 to about 2000, about 1000 to about 3000, or about 2000 to about 4000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for spleen is at least about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for spleen is at most about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.4 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for spleen is about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.075 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 2 ⁇ 10 ⁇ circumflex over (
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for spleen is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 10, at least about 12, at least about 14, at least about 21, at least about 28, at least about 35, at least about 42, at least about 49, or at least about 100 days.
  • the mean Tlast for spleen is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for spleen is at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, at most about 6, at most about 7, at most about 10, at most about 12, at most about 14, at most about 21, at most about 28, at most about 35, at most about 42, at most about 49, at most about 100 days, at most about 200, or at most about 300 days.
  • the mean Tlast for spleen is at most about 1, at most about 2, at most about 3, at most about 4,
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for spleen is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80 to about 100 days.
  • the mean Tlast for spleen is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T 1/2 for spleen is at least 6, at least 24, at least 48, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for spleen is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for spleen is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 4 hour at 0.3 mg/kg, after administration of a single dose to a male subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 24 hour at 0.6 mg/kg, after administration of a single dose to a male subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 24 hour at 0.6 mg/kg, after administration of a single dose to a female subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 48 hour at 1 mg/kg, after administration of a single dose to a male subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 48 hour at 1 mg/kg, after administration of a single dose to a female subject.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in heart is at least 0.5, at least 1, at least 2, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, or at least 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in heart is at most 6, at most 12, at most 16, at most 20, at most 24, at most 28, at most 32, at most 36, at most 40, at most 44, at most 48, at most 72, at most 96, or at most 120 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T max of the compound in heart is about 0.5 to about 120, about 1 to about 24, about 1 to about 36, about 1 to about 48, about 2 to about 36, about 6 to about 24, about 1 to about 6, about 6 to about 12, about 12 to about 24, about 12 to about 18, about 18 to about 48, about 18 to about 36, or about 24 to about 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean C max of the compound in heart is at least about 1, at least about 50, at least about 100, at least about 250, at least about 500, at least about 750, at least about 1250, at least about 1500, at least about 2000, at least about 2500, at least about 3000, at least about 5000, or at least about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean C max of the compound in heart is at most about 750, at most about 1000, at most about 1500, at most about 2000, at most about 2500, at most about 3000, at most about 4000, at most about 5000, or at most about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Cmax of the compound in heart is about 100 to about 50000, about 200 to about 5000, about 300 to about 4000, about 300 to about 3000, about 300 to about 1000, about 100 to about 2000, about 1000 to about 3000, or about 2000 to about 4000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUC last of the compound for heart is at least about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUClast of the compound for heart is at most about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.4 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean AUClast of the compound for heart is about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.075 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.09 ⁇ 10 ⁇ circumflex over (
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for heart is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 10, at least about 12, at least about 14, at least about 21, at least about 28, at least about 35, at least about 42, at least about 49, or at least about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for heart is at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, at most about 6, at most about 7, at most about 10, at most about 12, at most about 14, at most about 21, at most about 28, at most about 35, at most about 42, at most about 49, at most about 100 days, at most about 200, or at most about 300 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean Tlast for heart is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80 to about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T 1/2 for heart is at least 6, at least 24, at least 48, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T1 ⁇ 2 for heart is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.01 mg/kg to about 5 mg/kg (for example, about 0.1 to about 2 mg/kg, about 0.2 to about 1.5 mg/kg, about 0.3 to about 1.2 mg/kg, about 0.3 to about 1 mg/kg, about 0.3 to about 0.6 mg/kg, or about 0.6 to about 1 mg/kg), then the mean T1 ⁇ 2 for heart is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in heart is at least 0.5, at least 1, at least 2, at least 4, at least 8, at least 12, at least 16, at least 20, at least 24, at least 28, at least 32, at least 36, at least 40, at least 44, or at least 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in heart is at most 6, at most 12, at most 16, at most 20, at most 24, at most 28, at most 32, at most 36, at most 40, at most 44, at most 48, at most 72, at most 96, or at most 120 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T max of the compound in heart is about 0.5 to about 120, about 1 to about 24, about 1 to about 36, about 1 to about 48, about 2 to about 36, about 6 to about 24, about 1 to about 6, about 6 to about 12, about 12 to about 24, about 12 to about 18, about 18 to about 48, about 18 to about 36, or about 24 to about 48 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean C max of the compound in heart is at least about 1, at least about 50, at least about 100, at least about 250, at least about 500, at least about 750, at least about 1250, at least about 1500, at least about 2000, at least about 2500, at least about 3000, at least about 5000, or at least about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Cmax of the compound in heart is at most about 1000, at most about 1500, at most about 2000, at most about 2500, at most about 3000, at most about 4000, at most about 5000, or at most about 10000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Cmax of the compound in heart is about 100 to about 50000, about 200 to about 5000, about 300 to about 4000, about 500 to about 3000, about 500 to about 1000, about 1000 to about 2000, about 1000 to about 3000, or about 2000 to about 4000 ng/mL.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUC last of the compound for heart is at least about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at least about 0.3 ⁇
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUClast of the compound for heart is at most about 0.08 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.1 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.4 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, at most about 0.5 ⁇
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean AUClast of the compound for heart is about 0.01 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 5 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.05 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 3 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6, about 0.075 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6 to about 2 ⁇ 10 ⁇ circumflex over ( ) ⁇ 6,
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for heart is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 10, at least about 12, at least about 14, at least about 21, at least about 28, at least about 35, at least about 42, at least about 49, or at least about 100 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for heart is at most about 1, at most about 2, at most about 3, at most about 4, at most about 5, at most about 6, at most about 7, at most about 10, at most about 12, at most about 14, at most about 21, at most about 28, at most about 35, at most about 42, at most about 49, at most about 100 days, at most about 200, or at most about 300 days.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean Tlast for heart is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80 to about 100 days.
  • the mean Tlast for heart is about 1 to about 300, about 2 to about 100, about 5 to about 50, about 10 to about 30, about 1 to about 20, about 20 to about 40, about 40 to about 60, about 60 to about 80, or about 80
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T 1/2 for heart is at least 6, at least 24, at least 48, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for heart is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a pharmacokinetic study comprises administering (e.g., via intracerebroventricular administration) a compound of the disclosure to a study patient or subject at a dose amount of about 0.001 mg/kg to about 0.5 mg/kg (for example, about 0.008 to about 0.163 mg/kg, about 0.016 to about 0.125 mg/kg, about 0.025 to about 0.1 mg/kg, about 0.025 to about 0.08 mg/kg, about 0.025 to about 0.05 mg/kg, or about 0.05 to about 0.08 mg/kg), then the mean T1 ⁇ 2 for heart is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 48 hours at 0.3 mg/kg, after administration of a single dose to a male subject.
  • a pharmaceutical composition in unit dose form for intracerebroventricular delivery of a compound comprising a peptide nucleic acid sequence wherein the mean T max of the compound is within 70% to 130% of a T max of 24 hours at 0.3 mg/kg, after administration of a single dose to a female subject.
  • Biodistribution of compounds of the disclosure can be evaluated via methods that can directly or indirectly detect the presence of compound in tissue.
  • tissue of a subject administered a compound of the disclosure can be evaluated by mass spectroscopic methods, such as tandem mass spectrometry, whereby presence of compound in tissue samples can be evaluated on the basis of intensity of a signal corresponding to the mass of ionized compound or compound fragments.
  • Other methods suitable for determination of biodistribution include administration of a radiolabeled analogue of the compound, and evaluation of the radiographic signature of the analogue in the subject via imaging techniques such as autoradiography, positron emission tomography, or single-photon emission computed tomography.
  • biodistribution of a radiolabeled analogue is evaluated via quantitative whole body autoradiography (QWBA).
  • QWBA quantitative whole body autoradiography
  • an animal subject is administered the radiolabeled analogue, euthanized at a specified timepoint subsequent to administration, frozen, and suspended in embedding media such as aqueous sodium carboxymethyl cellulose.
  • the suspended carcass can be sectioned in a cryomacrotome, and the resulting sections can be mounted on an adhesive support and placed on an imaging plate sensitive to the specific radioisotope used in the radiolabeled analogue, such as carbon-14.
  • the exposed imaging plates can then be converted to electronic form using a phosphor imager system, and selected areas of the image file can be electronically integrated to provide concentrations of analogue expressed in ng-equivalents of compound per gram of tissue (ng-eq/g).
  • the QWBA assay can be repeated on multiple animal subjects, or selected parameters of the assay can be varied from animal to animal, such as dosage, route of administration, or time from compound administration to euthanization.
  • a QWBA can comprise three components, where one animal is euthanized four hours after administration of a radiolabeled analogue, a second animal is euthanized 12 hours after administration of the radiolabeled analogue, and a third animal is euthanized 7 days after administration of the radiolabeled analogue. Concentrations of the analogue in various tissues of each animal can then be determined and compared across each animal, thereby providing insight into the timecourse of biodistribution of the radiolabeled analogue and compound. In each study component, urine and feces of each subject animal can be collected and evaluated for radiolabeled analogue content.
  • a compound of the disclosure Upon systemic administration, a compound of the disclosure, or a radiolabeled analogue thereof can exhibit distribution into certain tissues, for example, as determined by quantitative whole-body autoradiography (QWBA).
  • QWBA quantitative whole-body autoradiography
  • an assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the compound can be distributed to, for example, kidney cortex, joints, cartilage, liver, salivary glands, bone surface, pancreas, hair follicles, large intestine mucosa, aortic wall, small intestine mucosa, adrenal gland, stomach mucosa, spleen, bone marrow, lymph nodes, thymus
  • the compound is administered (e.g., via single dose intravenous administration) to a study patient or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the compound can be distributed to, for example, Adrenal gland cortex, Adrenal gland medulla, Aortic wall, Bone inner, Bone surface, Bone marrow, Brain caudate, Brain cerebellum, Brain cortex, Brain lateral ventricle, Brain olfactory bulb, Brain putamen, Brain substantia nigra, Brain thalamus, Brown fat, Eye uveal tract (choroid+RPE), Hair follicles, Heart blood, Heart myocardium, Joints (cartilage),
  • Adrenal gland cortex Adrenal gland medulla
  • Aortic wall Bone
  • the disclosure provides a compound comprising a peptide nucleic acid sequence and a cell permeabilizing group attached to the peptide nucleic acid sequence.
  • an amount of the compound within the brain at seven, eight, nine, or ten days subsequent to the administration can be equivalent to at least 80% of an amount of the compound within the brain at 4 hours subsequent to the administration.
  • the amount of the compound within the brain at seven, eight, nine, or ten days subsequent to the administration is equivalent to at least 100% of the amount of the compound within the brain at 4 hours subsequent to the administration.
  • the amount of the compound within the brain at seven, eight, nine, or ten days subsequent to the administration is equivalent to at least 150% of the amount of the compound within the brain at 4 hours subsequent to the administration. In some embodiments, the amount of the compound within the brain at seven, eight, nine, or ten days subsequent to the administration is equivalent to at least 200% of the amount of the compound within the brain at 4 hours subsequent to the administration.
  • the disclosure provides a compound comprising a peptide nucleic acid sequence and a cell permeabilizing group attached to the peptide nucleic acid sequence.
  • an assay of a retention of the compound in a brain of a subject following administration of the compound to the subject least 80% of the compound present in the brain at 4 hours subsequent to the administration can remain in the brain for at least 7 days following the administration.
  • the assay is a quantitative whole body autoradiography assay.
  • the disclosure provides a compound comprising a peptide nucleic acid sequence and a cell permeabilizing group attached to the peptide nucleic acid sequence.
  • an amount of the compound within the skeletal muscle at seven, eight, nine, or ten days subsequent to the administration may be equivalent to at least 40% of an amount of the compound within the skeletal muscle at 4 hours subsequent to the administration.
  • the amount of the compound within the skeletal muscle at seven, eight, nine, or ten days subsequent to the administration is equivalent to at least 60% of the amount of the compound within the skeletal muscle at 4 hours subsequent to the administration.
  • the amount of the compound within the skeletal muscle at seven, eight, nine, or ten days subsequent to the administration is equivalent to at least 80% of the amount of the compound within the skeletal muscle at 4 hours subsequent to the administration. In some embodiments, the amount of the compound within the skeletal muscle at seven, eight, nine, or ten days subsequent to the administration is equivalent to at least 90% of the amount of the compound within the skeletal muscle at 4 hours subsequent to the administration.
  • the assay is a quantitative whole body autoradiography assay.
  • the disclosure provides a compound comprising a peptide nucleic acid sequence and a cell permeabilizing group attached to the peptide nucleic acid sequence.
  • an assay of a retention of the compound in skeletal muscle of a subject following administration of the compound to the subject least 80% of the compound present in the skeletal muscle at 4 hours subsequent to the administration can remain in the skeletal muscle for at least 7 days following the administration.
  • the assay is a quantitative whole body autoradiography assay.
  • a concentration of the compound in the brain of the subject is at least about 100 nanograms of the compound per gram of wet brain tissue, 200 nanograms of the compound per gram of wet brain tissue, 300 nanograms of the compound per gram of wet brain tissue, 400 nanograms of the compound per gram of wet brain tissue, 500 nanograms of the compound per gram of wet brain tissue, 600 nanograms of the compound per gram of wet brain tissue, 700 nanograms of the compound per gram of wet brain tissue, 800 nanograms of the compound per gram of wet brain tissue, 900 nanograms of the compound per gram of wet brain tissue, or 1000 nanograms of the compound per gram of wet brain tissue after about 4 hours subsequent to the administering.
  • a concentration of the compound in the brain of the subject is at least about 100 nanograms of the compound per gram of wet brain tissue, 200 nanograms of the compound per gram of wet brain tissue, 300 nanograms of the compound per gram of wet brain tissue, 400 nanograms of the compound per gram of wet brain tissue, 500 nanograms of the compound per gram of wet brain tissue, 600 nanograms of the compound per gram of wet brain tissue, 700 nanograms of the compound per gram of wet brain tissue, 800 nanograms of the compound per gram of wet brain tissue, 900 nanograms of the compound per gram of wet brain tissue, or 1000 nanograms of the compound per gram of wet brain tissue after about 7 days subsequent to the administering.
  • a concentration of the compound the brain of the subject is at least about 200 nanograms of the compound per gram of wet brain tissue after about 4 hours subsequent to the administering. In some embodiments, a concentration of the compound in the brain of the subject is at least about 200 nanograms of the compound per gram of wet brain tissue after about 7 days subsequent to the administering. In some embodiments, a concentration of the compound in the brain of the subject is at least about 100 nanomoles of the compound per liter after about 4 hours subsequent to the administering. In some embodiments, a concentration of the compound in the brain of the subject is at least about 100 nanomoles of the compound per liter after about 7 days subsequent to the administering.
  • a compound of the disclosure or a radiolabeled analogue thereof can exhibit a low rate of excretion.
  • an assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then less than about 20%, less than about 15%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2.5%, less than about 2%, less than about 1.9%, less than about 1.8%,
  • a compound of the disclosure e.g., Compound 1 or a radiolabele
  • an assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then less than about 20%, less than about 15%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2.5%, less than about 2%, less than about 1.9%, less than about 1.8%,
  • a compound of the disclosure e.g., Compound 1 or a radiolabele
  • an assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then less than about 20%, less than about 15%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2.5%, less than about 2%, less than about 1.9%, less than about 1.8%,
  • a compound of the disclosure e.g., Compound 1 or a radiolabele
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean T 1/2 for plasma is at least 6, at least 24, at least 48, at least 100, at least 125, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1)
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then a mean T 1/2 for plasma is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1)
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then a mean T 1/2 for plasma is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean C max of the compound in plasma is at least about 1, at least about 1000, at least about 2000, at least about 3000, at least about 4000, at least about 5000, at least about 6000, at least about 7000, at least about 8000, at least about 9000, at least about 10000, at least about 12000, at least about 14000, at least about 16
  • a radiolabeled analogue of a compound of the disclosure e.g.
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean C max of the compound in plasma is at most about 3000, at most about 4000, at most about 5000, at most about 6000, at most about 7000, at most about 8000, at most about 9000, at most about 10000, at most about 12000, at most about 14000, at most about 16000, at most
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean C max of the compound in plasma is about 1000 to about 50000, about 2000 to about 25000, about 3000 to about 22000, about 2000 to about 5000, about 5000 to about 15000, or about 10000 to about 25000 ng-eq/g.
  • a radiolabeled analogue of a compound of the disclosure e.g., [ 14 C]-Compound 1
  • a study patient e.g., a monkey
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean T 1/2 for plasma is at least 6, at least 24, at least 48, at least 100, at least 125, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a compound of the disclosure e.g., Compound 1
  • a radiolabeled analogue thereof e.g., [ 14
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then a mean T 1/2 for plasma is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a compound of the disclosure e.g., Compound 1
  • a radiolabeled analogue thereof e.g., [ 14 C
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then a mean T 1/2 for plasma is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean C max of the compound in plasma is at least about 1, at least about 1000, at least about 2000, at least about 3000, at least about 4000, at least about 5000, at least about 6000, at least about 7000, at least about 8000, at least about 9000, at least about 10000, at least about 12000, at least
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean C max of the compound in plasma is at most about 3000, at most about 4000, at most about 5000, at most about 6000, at most about 7000, at most about 8000, at most about 9000, at most about 10000, at most about 12000, at most about 14000, at most about 16000, at most about 18
  • a radiolabeled analogue of a compound of the disclosure e.g.
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean C max of the compound in plasma is about 1000 to about 50000, about 2000 to about 25000, about 3000 to about 22000, about 2000 to about 5000, about 5000 to about 15000, or about 10000 to about 25000 ng-eq/g.
  • a radiolabeled analogue of a compound of the disclosure e.g., [ 14 C]-Compound 1
  • a study patient e
  • the subject is a primate, a monkey, or a human.
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean T 1/2 for blood is at least 6, at least 24, at least 48, at least 100, at least 125, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1)
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then a mean T 1/2 for blood is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1)
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then a mean T 1/2 for blood is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient (e.g., monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean C max of the compound in blood is at least about 1, at least about 1000, at least about 2000, at least about 3000, at least about 4000, at least about 5000, at least about 6000, at least about 7000, at least about 8000, at least about 9000, at least about 10000, at least about 12000, at least about 14000, at least about 16000,
  • a radiolabeled analogue of a compound of the disclosure e.g.
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean C max of the compound in blood is at most about 3000, at most about 4000, at most about 5000, at most about 6000, at most about 7000, at most about 8000, at most about 9000, at most about 10000, at most about 12000, at most about 14000, at most about 16000, at most about 18000, at most about 20000, at most
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g [ 14 C]-Compound 1) to a study patient (e.g., a monkey) or subject at a dose amount of about 5 mg/kg (for example, about 0.05 to about 500 mg/kg, about 0.5 to about 50 mg/kg, about 1 to about 10 mg/kg, about 2 to about 8 mg/kg, about 3 to about 7 mg/kg, or about 4 to about 6 mg/kg), then the mean C max of the compound in blood is about 1000 to about 50000, about 2000 to about 25000, about 3000 to about 22000, about 2000 to about 5000, about 5000 to about 15000, or about 10000 to about 25000 ng-eq/g.
  • a radiolabeled analogue of a compound of the disclosure e.g [ 14 C]-Compound 1
  • a study patient e.g., a monkey
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g [ 14 C]-Compound 1) to a study patient or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean T 1/2 for blood is at least 6, at least 24, at least 48, at least 100, at least 125, at least 150, at least 200, at least 250, at least 300, at least 400, at least 500, or at least 1000 hours.
  • a compound of the disclosure e.g., Compound 1
  • a radiolabeled analogue thereof e.g [ 14 C]-Compound 1
  • the mean T 1/2 for blood
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g [ 14 C]-Compound 1) to a study patient or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then a mean T 1/2 for blood is at most 24, at most 48, at most 100, at most 200, at most 300, at most 400, at most 500, at most 600, at most 750, at most 1000, or at most 5000 hours.
  • a compound of the disclosure e.g., Compound 1
  • a radiolabeled analogue thereof e.g [ 14 C]-Compound 1
  • a mean T 1/2 for blood
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a compound of the disclosure (e.g., Compound 1) or a radiolabeled analogue thereof (e.g., [ 14 C]-Compound 1) to a study patient or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then a mean T 1/2 for blood is about 24 to about 20000, about 50 to about 15000, about 50 to about 1000, about 100 to about 500, about 100 to about 300, about 100 to about 200, about 200 to about 300, about 300 to about 400, about 400 to about 500, or about 3000 to about 5000 hours.
  • a compound of the disclosure e.g., Compound 1 or a radiolabeled analogue thereof (
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean C max of the compound in blood is at least about 1, at least about 1000, at least about 2000, at least about 3000, at least about 4000, at least about 5000, at least about 6000, at least about 7000, at least about 8000, at least about 9000, at least about 10000, at least about 12000, at least about 14000, at least about 16000,
  • a radiolabeled analogue of a compound of the disclosure e.g.
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean C max of the compound in blood is at most about 3000, at most about 4000, at most about 5000, at most about 6000, at most about 7000, at most about 8000, at most about 9000, at most about 10000, at most about 12000, at most about 14000, at most about 16000, at most about 18000, at most about 20000, at most
  • a study or assay comprises administering (e.g., via single dose intravenous administration) a radiolabeled analogue of a compound of the disclosure (e.g., [ 14 C]-Compound 1) to a study patient or subject at a dose amount of about 1.6 mg/kg (for example, about 0.015 to about 160 mg/kg, about 0.16 to about 16 mg/kg, about 0.3 to about 3.2 mg/kg, about 0.65 to about 2.6 mg/kg, about 1 to about 2.3 mg/kg, or about 1.3 to about 2 mg/kg), then the mean C max of the compound in blood is about 1000 to about 50000, about 2000 to about 25000, about 3000 to about 22000, about 2000 to about 5000, about 5000 to about 15000, or about 10000 to about 25000 ng-eq/g.
  • a radiolabeled analogue of a compound of the disclosure e.g., [ 14 C]-Compound 1
  • the mean C max of the compound in blood is about 1000 to about 50000
  • the subject is a primate, a monkey, or a human.
  • no more than 2% of the therapeutically-effective amount of the compound is excreted by the subject in urine over a 7 day period subsequent to the administering. In some embodiments, no more than 2% of the therapeutically-effective amount of the compound is excreted by the subject in feces over a 7 day period subsequent to the administering.
  • a compound of the disclosure can achieve full biodistribution without lipid nanoparticles.
  • the backbone is covalently modified such that the compound exhibits cell permeability that does not differ across cell types.
  • the backbone can be covalently modified with functional groups (e.g., guanidino groups) such that the compound exhibits cell permeability that does not significantly differ across cell types.
  • the plasma protein binding percentage is at least about 85% in one or more study patients. In some embodiments, the plasma protein binding percentage is at least about 85% in each of a human, mouse, dog, minipig, sheep, and/or monkey. In some embodiments, the plasma protein binding assay comprises performing the plasma protein binding assay on a study patient. In some embodiments, at a concentration of about 1 ⁇ g/mL, the plasma protein binding percentage is at least about 95% in the human, mouse, dog, minipig, sheep, and/or monkey. In some embodiments, at the concentration of about 1 ⁇ g/mL, the plasma protein binding percentage is at least about 95% in each of the human, mouse, dog, minipig, sheep, and monkey.
  • the plasma protein binding assay comprises spiking single aliquots of a study patient's plasma with a first solution of the compound (e.g., 10 mg/mL of the first solution of the compound) to obtain at least a second solution of the compound (e.g., with concentrations of about 1 ⁇ g/mL to about 50 ⁇ g/mL).
  • a separation technique e.g., ultracentrifugation
  • plasma protein binding percentage in the study patient's plasma can be determined using various techniques, disclosed herein, such as liquid chromatography-tandem mass spectrometry.
  • the plasma protein binding assay comprises performing a human component of the plasma protein binding assay.
  • the human component of the plasma protein binding assay comprises spiking single aliquots of human plasma with a first solution of the compound (e.g., 10 mg/mL of the first solution of the compound) to obtain at least a second solution of the compound (e.g., with concentrations of about 1 ⁇ g/mL to about 50 ⁇ g/mL).
  • a separation technique e.g., ultracentrifugation
  • a plasma protein binding percentage in the human plasma can be determine using various techniques, disclosed herein, such as liquid chromatography-tandem mass spectrometry.
  • a mouse component of the plasma protein binding assay is performed.
  • the mouse component of the plasma protein binding assay differs from the human component of the plasma protein binding assay only in that mouse plasma is used instead of the human plasma.
  • a dog component of the plasma protein binding assay is performed.
  • the dog component of the plasma protein binding assay differs from the human component of the plasma protein binding assay only in that dog plasma is used instead of the human plasma.
  • a minipig component of the plasma protein binding assay is performed.
  • the minipig component of the plasma protein binding assay differs from the human component of the plasma protein binding assay only in that minipig plasma is used instead of the human plasma.
  • a sheep component of the plasma protein binding assay is performed.
  • the sheep component of the plasma protein binding assay differs from the human component of the plasma protein binding assay only in that sheep plasma is used instead of the human plasma.
  • a monkey component of the plasma protein binding assay is performed.
  • the monkey component of the plasma protein binding assay differs from the human component of the plasma protein binding assay only in that monkey plasma is used instead of the human plasma.
  • a plasma binding protein assay e.g., in vitro plasma binding protein assay
  • the compound is assessed in plasma from a host species, (e.g., spiked into pooled plasma at a concentration of about 0.01, about 0.1, about 0.5, about 1, about 5, about 10, about 50, about 100, about 500, or about 1000 ⁇ g/mL)
  • the % binding of the compound to plasma proteins is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%
  • the host species can be, for example, mouse (e.g., C57BL6), dog (e.g., beagle), minipig (e.g., Gottingen minipig), sheep, monkey (e.g., Cynomolgus monkey), human, or any suitable animal disclosed herein.
  • mouse e.g., C57BL6
  • dog e.g., beagle
  • minipig e.g., Gottingen minipig
  • sheep e.g., Cynomolgus monkey
  • human e.g., Cynomolgus monkey
  • a plasma binding protein assay e.g., in vitro plasma binding protein assay
  • the compound is assessed in plasma from a host species, (e.g., spiked into pooled plasma at a concentration of about 0.01, about 0.1, about 0.5, about 1, about 5, about 10, about 50, about 100, about 500, or about 1000 ⁇ g/mL)
  • the % binding of the compound to plasma proteins is at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20%, at least about 21%, at least about 22%, at least about 23%, at least about 24%, at least about
  • the host species can be, for example, mouse (e.g., C57BL6), dog (e.g., beagle), minipig (e.g., Gottingen minipig), sheep, monkey (e.g., Cynomolgus monkey), human, or any suitable animal disclosed herein.
  • mouse e.g., C57BL6
  • dog e.g., beagle
  • minipig e.g., Gottingen minipig
  • sheep e.g., Cynomolgus monkey
  • human e.g., Cynomolgus monkey
  • a plasma binding protein assay e.g., in vitro plasma binding protein assay
  • the compound is assessed in plasma from a host species, (e.g., spiked into pooled plasma at a concentration of about 0.01, about 0.1, about 0.5, about 1, about 5, about 10, about 50, about 100, about 500, or about 1000 ⁇ g/mL)
  • the % binding of the compound to plasma proteins is at most about 1%, at most about 2%, at most about 3%, at most about 4%, at most about 5%, at most about 6%, at most about 7%, at most about 8%, at most about 9%, at most about 10%, at most about 11%, at most about 12%, at most about 13%, at most about 14%, at most about 15%, at most about 16%, at most about 17%, at most about 18%, at most about 19%, at most about 20%, at most about 21%, at most about 22%, at most about 23%, at most about 24%, at most about
  • the host species can be, for example, mouse (e.g., C57BL6), dog (e.g., beagle), minipig (e.g., Gottingen minipig), sheep, monkey (e.g., Cynomolgus monkey), human, or any suitable animal disclosed herein.
  • mouse e.g., C57BL6
  • dog e.g., beagle
  • minipig e.g., Gottingen minipig
  • sheep e.g., Cynomolgus monkey
  • human e.g., Cynomolgus monkey
  • a plasma binding protein assay e.g., in vitro plasma binding protein assay
  • the compound is assessed in plasma from a host species, (e.g., spiked into pooled plasma at a concentration of about 0.01, about 0.1, about 0.5, about 1, about 5, about 10, about 50, about 100, about 500, or about 1000 ⁇ g/mL)
  • the % binding of the compound to plasma proteins is about 0% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, about 90% to about 100%, about 0% to about 20%, about 0% to about 30%, about 0% to about 40%, about 0% to about 50%, about 0% to about 60%, about 0% to about 70%, about 0% to about 80%, about 0% to about 90%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about 10% to about 10% to about 10% to about
  • the host species can be, for example, mouse (e.g., C57BL6), dog (e.g., beagle), minipig (e.g., Gottingen minipig), sheep, monkey (e.g., Cynomolgus monkey), human, or any suitable animal disclosed herein.
  • mouse e.g., C57BL6
  • dog e.g., beagle
  • minipig e.g., Gottingen minipig
  • sheep e.g., Cynomolgus monkey
  • human e.g., Cynomolgus monkey
  • Plasma Protein Binding was assessed in pooled male plasma at nominal Compound 1 concentrations of 1, 10, and 50 ⁇ g/mL. The assay was performed using the ultrafiltration technique and the concentrations of Compound 1 were determined by LC MS/MS analysis. Warfarin was used as positive control to validate each ultrafiltration run.
  • K 3 EDTA was used as the anti-coagulant for both the species.
  • the separation of unbound Compound 1 from plasma proteins was performed using Centrifree® ultrafiltration devices with a 30,000 NMWL regenerated cellulose membrane.
  • PBS Phosphate Buffered Saline
  • Phosphate buffered saline was prepared at the concentration of 0.146 M. The pH was measured and found to be 7.40. PBS was stored at 4° C.
  • the stock solution (SS) containing Compound 1 at 10 mg/mL was prepared on.
  • SS was further diluted in PBS supplemented with 0.2% (v/v) formic acid to obtain the working solution WS1, 100 ⁇ g/mL.
  • Compound 1 SS and Compound 1 WS were stored at ⁇ 80° C.
  • a stock solution of warfarin (SS_W) was prepared in water: acetonitrile (50:50, v/v) at a nominal concentration of 3.24 mM (corresponding to 1 mg/mL). This solution was further diluted in the same solvent to obtain the working solution WS_W, 410 ⁇ M, which was used for plasma spiking.
  • Warfarin SS_W was stored at 4° C. (for not more than 21 days, as per method sheet). Warfarin WS_W was freshly prepared on each ultrafiltration occasion.
  • warfarin control sample 4.1 ⁇ M corresponding to 1265 ng/mL
  • Compound 1 The stability of Compound 1 was assessed at two test item concentrations (1 and 50 ⁇ g/mL) in all plasma species and in PBS by incubating each matrix for 15 min at 37° C. plus 4 hours at room temperature (time which covers incubation, ultrafiltration and sample treatment for analysis). Compound 1 concentrations were determined by LC-MS/MS analysis at both to and t 4h .
  • the inner wall was rinsed with 10% (v/v) Triton X-100 solution and left to dry for at least 1 hour before use.
  • the whole ultrafiltration devices, the ultrafiltrate reservoirs and the filtrate cups were weighed before adding the sample, after adding the sample (only for the whole ultrafiltration devices) and at the end of the centrifugation.
  • each ultrafiltration sample was checked for protein content to assess a possible protein contamination and then to confirm the filter integrity over ultrafiltration.
  • the presence of proteins was assessed in the ultrafiltrate using the Bradford method.
  • a calibration standard curve of bovine serum albumin was prepared at the following concentrations: 0, 50, 100, 200, 400, 600, 800, and 1000 ⁇ g/mL.
  • NBS Non-Specific Binding
  • NSB to ultrafiltration tubes was determined from the Compound 1 concentrations in PBS samples prior to centrifugation (C 0 ) and in the collected ultrafiltration samples after centrifugation (C u ).
  • V 0 initial volume of plasma sample, before ultrafiltration (mL)
  • V r volume of retentate, after ultrafiltration (mL)
  • V u volume of ultrafiltrate, after ultrafiltration (mL)
  • C 0 concentration in to plasma sample (ng/mL)
  • C r concentration in the retentate sample (ng/mL)
  • C u concentration in the ultrafiltrate sample (ng/mL)
  • the density of each matrix was assumed 1. The same calculations were performed for warfarin control sample.
  • NSB ⁇ 20% is acceptable.
  • Compound 1 was considered stable in plasma and PBS if the percentage difference between concentration after t 4h and t 0 is within ⁇ 15%.
  • Protein binding of the positive control warfarin should be ⁇ 98.0%.
  • the protein concentration measured after ultrafiltration should be ⁇ 0.3 mg/mL.
  • R Range of Recovery, % were assessed as detailed as follows: R ⁇ 200 or R ⁇ 50 means Experimental data not valid; 50 ⁇ R ⁇ 80 or 120 ⁇ R ⁇ 200 means Experimental data potentially unreliable; and 80 ⁇ R ⁇ 120 means Experimental data valid.
  • NBS Non-Specific Binding
  • NSB to filter membrane represented 20.5%, 6.2%, and 2.2% at 1, 10, and 50 ⁇ g/mL Compound 1 concentrations, respectively, indicating an increase of NSB contribution with decreasing concentration (which is the typical trend for compounds showing NSB). Since the NSB was not greater than around 20% (in the worst-case scenario), the ultrafiltration technique was deemed fit for purpose.
  • Compound 1 was stable (i.e., with a percentage loss not greater than 15%) in mouse, dog, sheep, monkey, and human plasma as well as PBS when incubated at room temperature for up to 4 hours at both 1 and 50 ⁇ g/mL.
  • Compound 1 was stable in minipig plasma at 1 ⁇ g/mL, whereas a slight instability (characterized by a percentage loss of 22.5%) was observed at 50 ⁇ g/mL.
  • PPB has been defined according to Busher's classification: very high (PPB ⁇ 98.0%), high (85.0% ⁇ PPB ⁇ 98.0%), and medium-to-low (PPB ⁇ 85.0%).
  • the matrix-matched samples were analyzed using three qualified bioanalytical LC-MS/MS methods: one for warfarin and two for Compound 1 (one for minipig and one for human, cynomolgus monkey, dog, sheep, and mouse).
  • Carry over was assessed throughout the study phase by injection of one or more blank samples after a high concentration standard. Carry over was more than 25% of the response at the LLOQ for Compound 1 and less than 5% for the internal standard. Carry over was more than 25% of the response at the LLOQ for warfarin and less than 5% for the internal standard. Study samples were analyzed following the expected concentration to avoid potential impact on the final results.
  • the objective of this study was to assess tissue distribution, disposition, and pharmacokinetics (PK) of [ 14 C]-Compound 1 drug related material following a single intravenous (IV) administration to the male cynomolgus ( Macaca fascicularis ) monkeys at the target dose level of 5 mg/kg using quantitative whole-body autoradiography (QWBA).
  • the cynomolgus monkey is representative of the distribution and excretion in a human.
  • Three animals were placed into metabolism cages after dosing and kept up to 4, 12, and 168 h post dose, respectively.
  • Pharmacokinetic profiles were obtained in blood and plasma collected from each animal at selected timepoints post-dose up to the terminal timepoint.
  • tissue distribution of [ 14 C]-Compound 1 was investigated using quantitative whole body autoradiography.
  • Total radioactivity in blood and plasma was quantifiable up to terminal timepoint in all animals. Over 168 h post dose (animal 103), systemic exposure to total radioactivity, measured as area under the plasma concentration time curve (AUC) from the start of dosing to the last quantifiable time point (T last ) (AUC 0-t ), was 231000 and 205000 h ⁇ ng-eq/g in blood and plasma, respectively, while maximum concentration (C max ) was 7510 ng-eq/g (C 0 9260 ng-eq/g) and 11500 ng-eq/g (C 0 14000 ng-eq/g), respectively. Total radioactivity showed higher partitioning into plasma than blood (blood to plasma ratio 0.6-0.8) except for 168 h where a ratio of 2.1 was observed.
  • AUC plasma concentration time curve
  • [ 14 C]-Compound 1 drug-related material was widely distributed throughout the whole body and quantifiable in all tissues up to the last timepoint sampled. The distribution pattern in tissues was comparable between selected timepoints over 168 h post-dose. Very high concentrations were observed in kidney cortex, joints (most likely connected to cartilage), and liver, suggesting potential accumulation in these tissues.
  • tissue that showed notable uptake were: salivary glands, bone surface, pancreas, hair follicles, large intestine mucosa, aortic wall, small intestine mucosa, adrenal gland, stomach mucosa, spleen, bone marrow, lymph nodes, and thymus.
  • brain to blood ratio ⁇ 1 total radioactivity distributed quite uniformly in relevant sub-regions (cerebellum, olfactory bulb, thalamus, caudate putamen, cerebral cortex, and substantia nigra), but the highest concentrations were measured in the lateral ventricle, most likely in the choroid plexus.
  • melanin e.g., hair follicles and, most importantly, the uveal tract in the eye
  • the radiolabeled test item supplied as powder (88.8 MBq corresponding to 81.9 mg), was dissolved in the vehicle (8.9 mL) to obtain a radioactive stock solution (SS) at a nominal concentration of 10 MBq/mL (9.2 mg/mL). Actual radioactivity concentration and radiochemical purity of SS was determined prior to use by liquid scintillation counting (LSC). SS was stored at ⁇ 80° C.
  • DPBS Dulbecco's Phosphate Buffered Saline (modified, without calcium chloride and magnesium chloride, liquid, sterile-filtered).
  • Osmolality 275-304 mOs/kg.
  • Target dose level 5.0 mg/kg
  • Target radioactive dose 147 ⁇ Ci/kg (5.42 MBq/kg)
  • Nominal radioactivity concentration 73.3 ⁇ Ci/mL (2.71 MBq/mL)
  • Residual Test Item Formulation The residual formulation was stored at ⁇ 20° C.
  • Body Weight 2.40 kg, 2.24 kg, 2.29 kg
  • Monkey was used as one of the non-rodent species required in toxicology studies by test guidelines.
  • the cynomolgus monkey was chosen because the non-human primate blood brain barrier is more similar to that of a human than to a dog blood brain barrier.
  • Diet was offered ad libitum throughout the study except for approximately 1 hour before and after dosing. A fruit, vegetable, and foraging mix supplement was also given.
  • LSC liquid scintillation counting
  • Intra-organ distribution of total radioactivity was evaluated in brain (cerebellum, olfactory bulb, thalamus, caudate putamen, cerebral cortex, and substantia nigra), eye and kidney. Sections were collected using a cryomacrotome, freeze-dried, and exposed to imaging plates. The resulting electronic whole-body autoradiograms were evaluated for the quantitative assessment of radioactivity in the tissues.
  • Radioactivity data in blood, plasma and tissues were subject to non-compartmental analysis for evaluation of appropriate pharmacokinetic parameters, where feasible.
  • the stability of the test item was assessed, by measuring the radiochemical purity, under the following conditions prior to initiating in-vivo experimental activities.
  • the stability of the final formulation was assessed at room temperature for 4 and 24 hours.
  • the radioactivity concentration of the stock solution and dose formulation was determined as follows: three weighed aliquots were dispensed into glass vials, appropriately diluted with DPBS. Three weighed aliquots were then removed from each dilution, supplemented with liquid scintillant and radioassayed by LSC in order to determine the actual radioactive concentration and homogeneity of the solutions.
  • the dose formulation was administered intravenously, as a bolus, through the caudal vein.
  • urine and feces were collected quantitatively at selected times post-dose and kept refrigerated, over wet ice, during collection.
  • metabolic cages were rinsed with ethanol/water (50:50, v/v) and the wash retained for quantitative determination of radioactivity.
  • Cage debris were collected and pooled by animal over the entire period of collection.
  • systemic blood was removed from the cephalic vein, at each selected time point post-dose and transferred into tubes containing K 3 EDTA as anti-coagulant (actual times of bleeding were recorded). Following collection, all blood samples were thoroughly mixed and placed on wet ice. Plasma samples were prepared within two hours of blood collection.
  • Feces were homogenized in a suitable quantity of ultrapure water (approximate ratio 1:2, w/v) using Stomacher homogenizer. Weighed quadruplicate aliquots of homogenates (0.2-0.4 g) were solubilized by addition of 1 mL of Solvable tissue solubilizer, supplemented twice with 200 ⁇ L of 30% hydrogen peroxide (H 2 O 2 ) and incubated at approximately 50° C., until appropriate discoloration was achieved, prior to addition of scintillant.
  • H 2 O 2 30% hydrogen peroxide
  • the remaining blood was centrifuged at 2000 g for 10 min at approximately 4° C. within two hours of collection and the plasma decanted into plastic tubes. Aliquots of plasma were radio assayed by LSC. Blood pellets were discarded.
  • Radioactivity was determined in a Tricarb Series liquid scintillation analyzer. Quench correction was achieved during sample counting through the automatic assignment of a quench indicator (tSIE/AEC) value to the sample. This value was used to interpolate sample counting efficiency from an instrument stored quench curve generated from a series of sealed quenched standards. The interpolated efficiency value was used to automatically correct LSC data counts per minute (cpm) and obtain disintegrations per minute (dpm). A suitable scintillation fluid (Ultima Gold) was added to each sample prior to radio assaying by LSC for an appropriate time. Background counts were subtracted from quench corrected sample counts. According to the background value and count time, the limit of quantification was calculated.
  • tSIE/AEC quench indicator
  • mice were frozen by immersion into a freezing mixture of hexane/solid CO 2 . Animals were left in the freezing mixture for at least 2 hours, until completely frozen.
  • Frozen carcasses were embedded, left lateral side uppermost, in a block of sodium carboxymethylcellulose (approximately 2%, w/v in water).
  • Each block was mounted in a CM3600 cryomacrotome (Leica Microsystems) maintained at approximately ⁇ 20° C. After initial trimming of the block, sagittal whole body sections (40 ⁇ m) were obtained at various levels through the carcass. Sections of interest mounted on pressure sensitive tape were left to dehydrate in the cryomacrotome chamber at approximately ⁇ 20° C. for approximately 60 h.
  • IP image plate
  • Freeze dried sections were placed against an image plate (IP), suitable for 14 C, as long as 4 days.
  • IPs were placed in a copper-lead shielding box for minimizing external background signals.
  • the IPs were scanned by a laser beam, using a Fuji FLA5000 phosphor imager system, and the latent image captured and stored on an electronic data file.
  • Results generated from the integration were expressed as Bq/g and subsequently converted to ng-equivalents of Compound 1/g tissue (ng-eq/g), using dose formulation specific activity.
  • the limit of quantification (LOQ) for tissue distribution was set as 3 times the mean background levels of radioactivity (mean of seven measurements per IP).
  • a block of frozen CMC (approximately 2%, w/v, in water) containing standards of known radioactivity was prepared on a separate occasion.
  • a series of paper straws were fixed in the block and monkey blood containing increasing amounts of a [ 14 C]-Compound 1 was dispensed into the straws and frozen.
  • the range of calibration standards was chosen to cover the extent of likely tissue concentration values (actual range 56.8-32,274 Bq/g).
  • Calibration lines were generated for each set of sections exposed on a single IP by selecting an area of each standard from the scanned image and assigning the corresponding radioactivity concentration previously determined by LSC.
  • Radioactivity concentration and the radiochemical purity of the stock solution was checked prior to use. Radioactivity concentration (MBq/mL) was 9.52. Radiochemical purity was 93.2%.
  • Compound 1 was stable under the experimental conditions assessed.
  • CL was 6.69 mL/h/kg (blood) and 14.0 mL/h/kg (plasma) and was significantly lower than were hepatic and renal blood flow rates (which are approximately 2616 and 1656 mL/h/kg). Consistently, mean V ss accounting for 2480 mL/kg (blood) and 2780 mL/kg (plasma) was significantly greater than was total body water in cynomolgus monkey (which is approximately 693 mL/kg). This result indicated moderate (0.6 to 5 L/kg) distribution into tissues.
  • the elimination phase could not be defined because of very limited elimination over 168 h post-dose.
  • acceptance criteria for terminal half-life T 1/2 were not fully met and total radioactivity T 1/2 could not be reliably calculated: estimates of 229 and 141 h in blood and plasma, respectively.
  • FIG. 3 and FIG. 4 illustrate concentrations of total radioactivity in representative organs and tissues at various times following single intravenous bolus of [ 14 C]-Compound 1 to male cynomolgus monkeys at 5 mg/kg.
  • FIG. 5 and FIG. 6 illustrate tissue to blood ratios at various times following single intravenous bolus of radiocarbon-Compound 1 ([ 14 C]-Compound 1) to male cynomolgus monkeys at 5 mg/kg.
  • FIG. 7A , FIG. 7B , FIG. 8A , FIG. 8B , FIG. 9A , FIG. 9B , FIG. 10A , and FIG. 10B are autoradiographs that depict representative tissue distribution of total radioactivity in midsagittal parasagittal sections of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 11 is an autoradiograph that depicts representative tissue distribution of total radioactivity in a mid-sagittal section of Animal 101 following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Approximate concentrations of [ 14 C]-Compound 1 in labelled regions of FIG.
  • 11 are as follows: 50 ng/g: 1 (Eye); 100 ng/g: 2 (Trachea), 3 (TA); 210 ng/g: 4 (Stomach), 5 (Brain), 6 (Putamen), 7 (Caudate), 8 (Substantia Nigra), 9 (Lateral Ventricle); 420 ng/g: 10 (Cortex), 11 (Spiral cord); 870 ng/g: 12 (Skeletal muscle), 13 (Lung), 14 (Bladder), 15 (Olfactory bulb), 16 (Cerebellum); 1600 ng/g: 17 (Kidney medulla), 18 (Intestine), 19 (Heart (myocardium)), 20 (Spinal cord), 21 (Aorta), 22 (Cardiac blood); 3600 ng/g: 23 (Mesenteric lymph nodes), 24 (Skin), 25 (Pituitary); 7100 ng/g: 26 (Spleen), 27 (Adrenal gland
  • FIG. 12A and FIG. 12B are autoradiographs that depict representative tissue distribution of total radioactivity in sagittal sections of Animal 101 (4 hours post dose), Animal 102 (12 hours post dose), Animal 103 (7 days post dose) following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 13 are autoradiographs that depict representative cranial tissue distribution of total radioactivity in selected sagittal sections of Animal 101 (4 hours post dose), Animal 102 (12 hours post dose), Animal 103 (7 days post dose) following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • FIG. 14 are autoradiographs that depict representative pelvic-area tissue distribution of total radioactivity in selected sagittal sections of Animal 101 (4 hours post dose), Animal 102 (12 hours post dose), Animal 103 (7 days post dose) following a single intravenous 5 mg/kg bolus of [ 14 C]-Compound 1. Any grey signal above background indicates presence of compound in tissues.
  • kidney cortex 125167 ng-eq/g, T/B 99.3
  • joints likely connected with cartilage, 59612 ng-eq/g, T/B 47.3
  • liver 34695 ng-eq/g, T/B 27.5.
  • T/B ⁇ 5 salivary glands (parotid T/B 14.2; others T/B 12.0), bone surface and pancreas (T/B 13.9), hair follicles (T/B 11.7), large intestine mucosa (T/B 9.8), aortic wall (T/B 9.3), small intestine mucosa (T/B 8.3), adrenal cortex (T/B 8.2), stomach mucosa (T/B 7.2), spleen (T/B 6.6), bone marrow (T/B 5.9), and lymph nodes (T/B 5.8).
  • kidney cortex 145490 ng-eq/g, T/B 99.1
  • joints (130483 ng-eq/g, T/B 88.9)
  • liver (56919 ng-eq/g, T/B 38.8) were still the most exposed tissues and attained the highest concentration.
  • T/B>5 salivary glands (parotid T/B 13.3; others T/B 9.1), pancreas (T/B 6.8), adrenal cortex and stomach mucosa (T/B 10.9), small intestine mucosa (T/B 10.5), hair follicles (T/B 10.3), lymph nodes (T/B 9.6), bone marrow (T/B 9.2), large intestine mucosa (T/B 8.9), aortic wall and spleen (T/B 6.3), adrenal medulla (T/B 5.3), and thymus (T/B 5.2), compared to a cardiac blood concentration of 1468 ng-eq/g.
  • [ 14 C]-Compound 1 showed moderate brain penetration (T/B ⁇ 1) and appeared to distribute uniformly throughout the tissue and in all sub-regions analyzed (cerebellum, olfactory bulb, thalamus, caudate putamen, cerebral cortex, and substantia nigra). The highest concentrations were measured in the lateral ventricle instead: 3763, 3781, 2868 ng-eq/g at 4, 12, and 168 h post-dose, respectively. This radioactivity was most likely connected to the choroid plexus within the ventricle.
  • [ 14 C]-Compound 1 approximately equally partitioned between blood and uveal tract (choroid+retinal pigmented epithelium) in the eye (2416 ng-eq/g (T/B 1.9), 2366 ng-eq/g (T/B 1.6), 1286 ng-eq/g (T/B 0.8) at 4, 12, and 168 h post-dose, respectively). These observations indicated potential melanin binding. Consistently, high concentrations were also measured in the hair follicles.
  • [ 14 C]-Compound 1 showed moderate (0.6 to 5 L/kg) volume of distribution and low clearance, thus the elimination half-life T 1/2 could not be reliably calculated. T 1/2 estimates were 229 and 141 h in blood and plasma, respectively.
  • [ 14 C]-Compound 1 drug-related material was widely distributed throughout the whole body and quantifiable in all tissues up to the last timepoint sampled. The distribution pattern in tissues was comparable between selected timepoints over 168 h post-dose. Very high concentrations were observed in kidney cortex, joints (most likely connected to cartilage), and liver, suggesting potential accumulation in these tissues.
  • tissue that showed notable uptake were salivary glands, bone surface, pancreas, hair follicles, large intestine mucosa, aortic wall, small intestine mucosa, adrenal gland, stomach mucosa, spleen, bone marrow, lymph nodes, and thymus.
  • brain to blood ratio ⁇ 1 total radioactivity distributed quite uniformly in relevant sub-regions (cerebellum, olfactory bulb, thalamus, caudate putamen, cerebral cortex, and substantia nigra), but the highest concentrations were measured in the lateral ventricle, most likely in the choroid plexus.
  • radioactivity was also measured in tissues containing melanin (e.g., hair follicles and the uveal tract in the eye), indicating potential binding to melanin.
  • melanin e.g., hair follicles and the uveal tract in the eye
  • the objective of this study was to assess the pharmacokinetics and tissue distribution of Compound 1 in male and female C57BL6J mice following single intracerebroventricular (ICV) administration at 0.6, 1, and 2 mg/kg.
  • ICV intracerebroventricular
  • Compound 1 was quantifiable up to 648 hours after dosing (last collected PK timepoint) in the brain across doses and in the heart at 0.3 mg/kg only in both sexes and up to at least 312 hours after dosing in the spleen across doses in both sexes. The result indicated accumulation of test item in these tissues. Generally, Compound 1 was not quantifiable in plasma, intestine, liver, lung, kidney, and muscle across doses and in both sexes.
  • Mean composite C max in the female and male brain was 3930 ng/mL and 3110 ng/mL at 0.3 mg/kg, 11400 ng/mL and 6490 ng/mL at 0.6 mg/kg, and 21500 ng/mL and 15500 ng/mL at 1 mg/kg, respectively.
  • Mean composite AUC last in the female and male brain was 1800000 ng ⁇ h/mL and 1440000 ng ⁇ h/mL at 0.3 mg/kg, 2360000 ng ⁇ h/mL and 2470000 ng ⁇ h/mL at 0.6 mg/kg, and 7150000 ng ⁇ h/mL and 5530000 ng ⁇ h/mL at 1 mg/kg, respectively.
  • Mean composite C max in the female and male spleen was 586 ng/mL and 756 ng/mL at 0.3 mg/kg, 984 ng/mL and 1530 ng/mL at 0.6 mg/kg, and 2270 ng/mL and 2940 ng/mL at 1 mg/kg, respectively.
  • Mean composite AUC last in the female and male spleen was 96500 ng ⁇ h/mL and 48300 ng ⁇ h/mL at 0.3 mg/kg, 98300 ng ⁇ h/mL and 166000 ng ⁇ h/mL at 0.6 mg/kg, and 449000 ng ⁇ h/mL and 1010000 ng ⁇ h/mL at 1 mg/kg, respectively.
  • Mean composite C max in the female and male heart was 729 ng/mL and 416 ng/mL and mean composite AUC last in the female and male heart was 184000 ng ⁇ h/mL and 160000 ng ⁇ h/mL, respectively.
  • the exposure (as mean composite C max and AUC last ) increased in brain in a proportional way as AUC last and slightly supra-proportionally as C max and in spleen in a proportional way as mean composite C max and supra-proportionally as mean composite AUC in both sexes.
  • Compound 1 was quantifiable in the spleen and liver up to 8 hours after dosing (last collected PK timepoint), in the intestine, kidney, and lung only at 8 hours after dosing, in plasma only at 4 hour after dosing. The compound was not quantifiable in muscle and heart in both sexes.
  • Compound 1 was not quantifiable in urine and feces across doses and in both sexes.
  • DPBS Dulbecco's Phosphate Buffered Saline (modified, without calcium chloride and magnesium chloride, liquid, sterile-filtered).
  • Osmolality 275-304 mOs/kg.
  • test item was dissolved in the vehicle.
  • the formulation was prepared dissolving the received amount of test item in the required amount of vehicle.
  • a stock formulation at 10 mg/mL was prepared in advance and divided in aliquots. Each aliquot was then diluted at the different needed concentrations for each administration route.
  • the dilutions were prepared before the first day of administration for each session of administration/route. On the day of preparation of the dilutions, the stock formulation was thawed at AT and heated at approx. 65° C. for 5 minutes, then allowed to cool to room temperature before use. After stirring the formulation was used for the dilutions.
  • the diluted formulations were stored at AT (at least three days) in Dispensary and used according to the scheduled time-points.
  • pH Range (measured only after the first preparation): 1.5 mg/mL: 6.75; 3 mg/mL: 6.68; 5 mg/mL: 6.26; 10 mg/mL: 3.75.
  • Residual Test Item Formulations residual formulations were discarded at the end of the dosing.
  • mice 100 male and 96 female mice
  • Type of Accommodation Solid bottom plastic cages containing sawdust litter.
  • Number per Cage 4 of the same sex, treatment group, and timepoint per cage.
  • Minimum Acclimatization At least 5 days (prior to dosing).
  • Water Source Filtered from normal domestic supply.
  • Relative Humidity Range 45-65% (40-70% for less than 24 hours acceptable).
  • Lighting Fluorescent lighting from approximately 06:00 to 18:00 hours daily.
  • the study design included 100 male and 96 female na ⁇ ve C57BL6J mice and four dose levels (0.3, 0.6, 1, and 2 mg/kg). Thirty-two males and 32 females received each a single ICV administration of Compound 1 at 0.6 and 1 mg/kg. Twelve males received each a single ICV administration of Compound 1 at 2 mg/kg and twenty-four males and 32 females received each a single ICV administration of Compound 1 at 0.3 mg/kg. Mice were anaesthetized with isofluorane and the skin incised in the upper part of the skull to make the bregma visible. The injection into the intracerebral ventricle was performed using a microsyringe equipped with a 27G needle.
  • the skin was sutured.
  • An anesthetic ointment was applied to the skin of the skull to limit the pain resulting from the incision. Dosing was performed in the presence of a veterinary to observe whether any clinical signs were noted.
  • the dose formulation was administered by volume.
  • the dose volume administered was 5 ⁇ L/mice.
  • Formulations were maintained at ambient room temperature up to the end of the dosing procedure.
  • the target dose levels are detailed in TABLE 12.
  • the dose formulation was administered via ICV route. Mice were anaesthetized with isofluorane and the skin incised in the upper part of the skull to make the bregma visible.
  • the injection into the intracerebral ventricle was performed using a microsyringe equipped with a 27G needle. At the end of the administration, the skin was sutured. An anesthetic ointment was applied to the skin of the skull to limit the pain resulting from the incision.
  • terminal blood samples were collected from cava vein of each animal at the following timepoints:
  • Day 1 1.5 hour, 4 hours, 8 hours and 24 hours after dosing; Day 3 corresponding to 48 hours after dosing; Day 7 corresponding to 144 hours after dosing; Day 14 corresponding to 312 hours after dosing; and Day 28 corresponding to 648 hours after dosing.
  • brain including cerebellum, liver, lung, kidneys (both), heart, small intestine, spleen, and skeletal muscle were collected from each animal at the following timepoints:
  • Day 1 1.5 hour, 4 hours, 8 hours, and 24 hours after dosing; Day 3 corresponding to 48 hours after dosing; Day 7 corresponding to 144 hours after dosing; Day 14 corresponding to 312 hours after dosing; and Day 28 corresponding to 648 hours after dosing.
  • Gall bladder was removed from the liver before organ weight. Small intestine was flushed with saline solution. Quadriceps femoris muscle from both legs were collected.
  • tissue samples were weighed, and the weight was recorded. Tissue samples were rinsed in saline solution, transferred in polypropylene tubes or wrapped in aluminum foils and immediately frozen at ⁇ 80° C.
  • Urine and feces were obtained from 4 males (except for Group 4 for which urine and feces were obtained from 3 males) and 4 females placed in metabolic cages (food and water were left ad libitum) over 24 hours before euthanasia at the following timepoints:
  • Day 1 24 hours after dosing; Day 3 corresponding to 48 hours after dosing; Day 7 corresponding to 144 hours after dosing; Day 14 corresponding to 312 hours after dosing; and Day 28 corresponding to 648 hours after dosing.
  • Urine and feces were collected in plastic tubes and frozen over solid carbon dioxide or in a freezer at ⁇ 80° C. (nominal).
  • Samples were assayed for Compound 1 using a qualified method based on protein precipitation followed by LC-MS/MS analysis.
  • Plasma and tissue PK elaboration were performed by non-compartmental pharmacokinetics analysis using Phoenix WinNonlin.
  • the following parameters for test item, when feasible, were determined using the linear logarithmic trapezoidal rule:
  • Plasma concentrations and PK parameters are expressed in terms of Compound as parent compound. Doses and temperatures are reported as nominal. The numerical data presented in this report are computer generated.
  • Not quantifiable (NQ) values at early timepoints up were set to zero and included in the profiles, otherwise removed. Not quantifiable (NQ) values were treated as follows in the calculation of the composite mean concentration values:
  • AUC last and C max values were reported with three significant digits; T max and T last were displayed as the corresponding nominal times.
  • FIG. 15A The mean concentrations of Compound 1 in the brain samples are shown graphically in FIG. 15A for doses of 0.3 mg/kg, FIG. 15B for doses of 0.6 mg/kg, FIG. 15C for doses of 1 mg/kg.
  • FIG. 16A The mean concentrations of Compound 1 in the spleen samples are shown graphically in FIG. 16A for doses of 0.3 mg/kg, FIG. 16B for doses of 0.6 mg/kg, FIG. 16C for doses of 1 mg/kg.
  • the mean concentrations of Compound 1 in the heart samples are shown graphically in FIG. 17 for doses of 0.3 mg/kg.
  • FIG. 18A Mean brain, spleen, and heart concentrations versus time profiles in male and female C57BL6J mice are presented graphically in FIG. 18A for doses of 0.3 mg/kg, FIG. 18B for doses of 0.6 mg/kg, FIG. 18C for doses of 1 mg/kg.
  • Compound 1 was quantifiable in the brain up to 648 hours after dosing (last collected PK timepoint) across doses and in both sexes. T max ranged between 1.5 and 48 hours after dosing in both sexes across dose range evaluated.
  • Mean composite C max in the female and male brain was 3930 ng/mL and 3110 ng/mL at 0.3 mg/kg, 11400 ng/mL and 6490 ng/mL at 0.6 mg/kg, and 21500 ng/mL and 15500 ng/mL at 1 mg/kg, respectively.
  • Mean composite AUC last in the female and male brain was 1800000 ng ⁇ h/mL and 1440000 ng ⁇ h/mL at 0.3 mg/kg, 2360000 ng ⁇ h/mL and 2470000 ng ⁇ h/mL at 0.6 mg/kg, and 7150000 ng ⁇ h/mL and 5530000 ng ⁇ h/mL at 1 mg/kg, respectively.
  • Compound 1 was quantifiable in the spleen up to 648 hours after dosing (last collected PK timepoint) in females at 0.3 and 0.6 mg/kg and in males at 1 mg/kg, up to 312 hours in males at 0.6 mg/kg and in females at 1 mg/kg and up to 144 hours in males at 0.3 mg/kg.
  • T max ranged between 4 and 48 hours after dosing in both sexes across the dose range evaluated.
  • Mean composite C max in the female and male spleen was 586 ng/mL and 756 ng/mL at 0.3 mg/kg, 984 ng/mL and 1530 ng/mL at 0.6 mg/kg, and 2270 ng/mL and 2940 ng/mL at 1 mg/kg, respectively.
  • Mean composite AUC last in the female and male spleen was 96500 ng ⁇ h/mL and 48300 ng ⁇ h/mL at 0.3 mg/kg, 98300 ng ⁇ h/mL and 166000 ng ⁇ h/mL at 0.6 mg/kg, and 449000 ng ⁇ h/mL and 1010000 ng ⁇ h/mL at 1 mg/kg, respectively.
  • Compound 1 was quantifiable in the spleen up to 8 hours after dosing (last collected PK timepoint), with concentrations 1.4-fold higher than those observed at the same timepoints in males given 1 mg/kg.
  • Compound 1 was quantifiable in the heart up to 648 hours after dosing (last collected PK timepoint) only at 0.3 mg/kg and up to 4 hours after dosing at 0.6 mg/kg in both sexes. T max occurred at 24 and 48 hours after dosing in females and males, respectively.
  • Mean composite C max in the female and male heart was 729 ng/mL and 416 ng/mL.
  • Mean composite AUC last in the female and male heart was 184000 ng ⁇ h/mL and 160000 ng ⁇ h/mL.
  • Compound 1 was not quantifiable in plasma at all timepoints across doses and in both sexes.
  • Compound 1 was quantifiable in plasma only at 4 hour after dosing.
  • Compound 1 Following a single ICV administration of Compound 1 at 0.3, 0.6, and 1 mg/kg to male and female mice, generally Compound 1 was not quantifiable in the liver across dose range and in both sexes.
  • Compound 1 was quantifiable in liver up to 8 hours after dosing (last point of tissue collection).
  • Compound 1 was not quantifiable in kidney across doses and in both sexes.
  • Compound 1 was quantifiable in kidney only at 8 hours after dosing (last point of tissue collection).
  • Compound 1 Following a single intracerebroventricular administration of Compound 1 at 0.3, 0.6, and 1 mg/kg to male and female mice, generally Compound 1 was not quantifiable in the intestine across doses and in both sexes.
  • Compound 1 was not quantifiable in the lung across dose range and in both sexes.
  • Compound 1 was quantifiable in lung only at 8 hours after dosing (last point of tissue collection).
  • Compound 1 Following a single ICV administration of Compound 1 at 0.3, 0.6, and 1 mg/kg to male and female mice and at 2 mg/kg to male mice, generally Compound 1 was not quantifiable in muscle across dose range and in both sexes.
  • Compound 1 was not quantifiable in the feces across doses and in both sexes.
  • Compound 1 was quantifiable up to 648 hours after dosing (last collected PK timepoint) in the brain across doses and in the heart only at 0.3 mg/kg in both sexes and up to at least 312 hours after dosing in the spleen across doses in both sexes. The result indicates accumulation of test item in these tissues. Generally, Compound 1 was not quantifiable in plasma, intestine, liver, lung, kidney, and muscle across doses and in both sexes.
  • Maximum concentration of Compound 1 occurred between 1.5 and 48 hours after dosing in brain and between 4 and 48 hours in spleen and in both sexes and across dose range evaluated and at 24 and 48 hours after dosing in heart in females and males, respectively.
  • Compound 1 was quantifiable in the spleen and liver up to 8 hours after dosing (last collected PK timepoint) and in the intestine, kidney and lung only at 8 hours after dosing, in plasma only at 4 hour after dosing. The compound was not quantifiable in muscle and heart in both sexes.
  • Compound 1 was not quantifiable in urine and feces across doses and in both sexes.
  • This example demonstrates the ability of illustrative compounds of the disclosure to reduce selectively and potently expression of mutant Huntington's disease protein in cells without causing cytotoxicity.
  • a human subject-derived fibroblast cell line GM09197 was obtained from the Coriell Institute (Coriell Institute for Medical Research, Camden, N.J.).
  • the first huntingtin allele in this cell line is a mutant huntingtin allele with 151 CAG repeats (mHTT), which is associated with development of Huntington's disease.
  • the second huntingtin allele in this cell line contains 21 CAG repeats. In some embodiments, this level can be considered a normal or wild type huntingtin allele (wtHTT) that is not considered to cause Huntington's disease.
  • Cells were maintained at 37° C. and 5% CO 2 in minimal essential media (MEM) supplemented with non-essential amino acids (Corning Inc, Corning N.Y., cat. n #10-009-CV) and 10% heat inactivated FBS (Corning Inc., Corning N.J. cat. n #35-016-CV).
  • MEM minimal essential media
  • PNA Peptide nucleic acid
  • Cells were plated in 24-well plates at 150,000 cells/well in supplemented MEM one day before addition of PNA. Stock solutions of PNA were heated at 80° C. for 10 min before use and were added to final concentrations of 1 ⁇ M or 5 ⁇ M in the cell cultures. Cells were incubated for 3 days in the presence or absence of PNA compound before evaluation of huntingtin knockdown and cytotoxicity.
  • Tris Glycine Running Buffer 0.1% SDS pH8.3 (Glycine cat. n #G8898, Sigma-Aldrich, St Louis Mo., Tri-Base cat. n #BP152-500, Fisher Scientific, Hampton, N.H., SDS 10% solution cat. n #1610416, Bio-Rad Laboratories, Hercules, Calif.). Gels were run at 165V for 2 hours. After gel electrophoresis, proteins were transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, Calif., cat. n #1620112).
  • a huntingtin-specific primary antibody was used to bind specifically both mHTT and wtHTT (1:2500, Abcam, Cambridge UK, cat. n #ab109115), with a beta-actin-specific primary antibody as a control (1:5000, Abcam Cambridge, UK, cat. n #ab8227).
  • Horseradish peroxidase (HRP) conjugated anti-mouse or anti-rabbit secondary antibodies (1:10,000, Jackson ImmunoResearch Laboratories, West Grove, Pa., cat. n #315-035-0003 and 111-035-045) were used for visualizing proteins using SuperSignal West Pico Plus Chemiluminescent Substrate (Thermo Fischer Scientific, Waltham, Mass., cat. n #34577).
  • Protein bands were quantified using iBright Analysis Software (Thermo Fischer Scientific, Waltham, Mass.). mHTT and wtHTT bands were normalized according to beta-actin expression, and mHTT and wtHTT expression inhibition was calculated as a relative value to untreated control cells.
  • FIG. 19A shows the relative expression of wtHTT (darker bars) and mHTT (lighter bars) after treatment with Compound 2 at 1 or 5
  • the figure demonstrates knockdown of both mHTT and wtHTT at 5 with somewhat greater knockdown of mHTT than wtHTT.
  • FIG. 19B shows the relative expression of wtHTT (darker bars) and mHTT (lighter bars) after treatment with Compound 3 at 1 or 5
  • the figure demonstrates knockdown of mHTT and wtHTT, with higher selectivity for mHTT compared to wtHTT at 1
  • These results also show that Compound 3 exhibited greater potency than Compound 2 for mHTT knockdown in this assay.
  • FIG. 19C shows the relative expression of wtHTT (darker bars) and mHTT (lighter bars, not visible) after treatment with Compound 4 at 1 or 5
  • the mHTT bars are not visible as mHTT was below the limit of detection.
  • LDH Lactate Dehydrogenase
  • 10 ⁇ Lysis Buffer was added to control wells comprising the GM09197 cells, and the plate was incubated at 37° C., 5% CO 2 for 50 min.
  • the percent of dead cells detected following treatment with the PNA compounds was not significantly different than that of untreated control. The result indicates that cytotoxicity was not observed for GM09197 cells treated with PNA compounds of the disclosure Compound 2 ( FIG. 20A ), Compound 3 ( FIG. 20B ), and Compound 4 ( FIG. 20C ) at doses that were effective to knock down mHTT.
  • PNA compounds of the disclosure were administered to non-human primates intravenously via a single tail vein injection per animal.
  • the single dose injections were well tolerated at doses of up to 5 mg/kg.
  • PNA compounds of the disclosure were administered via intraperitoneal injection into mice three times per week. Three times weekly doses of up to 2 mg/kg were well tolerated for up to five weeks.
  • Embodiment 1 A compound comprising a chain, wherein the chain comprises a series of atoms concatenated to form the chain, wherein a plurality of the atoms that are concatenated to form the chain are each independently substituted with a substituent that bears a guanidino group, wherein the chain has a pattern of one atom that is independently substituted with a substituent that bears a guanidino group, followed by five consecutive atoms that are not substituted by a substituent that bears a guanidino group, followed by a second atom that is independently substituted with a substituent that bears a guanidino group, followed by another five consecutive atoms that are not substituted by a substituent that bears a guanidino group, followed by a third atom that is independently substituted with a substituent that bears a guanidino group, wherein a first end of the chain or a second end of the chain is substituted with a peptide
  • Embodiment 2 The compound of embodiment 1, wherein the pattern further comprises one atom that is independently substituted with a substituent that bears a first nucleobase, followed by five consecutive atoms that are not substituted by a substituent that bears a nucleobase, followed by a second atom that is independently substituted with a substituent that bears a second nucleobase, followed by another five consecutive atoms that are not substituted by a substituent that bears a nucleobase, followed by a third atom that is independently substituted with a substituent that bears a third nucleobase.
  • Embodiment 3 The compound of embodiment 1 or embodiment 2, wherein each substituent that bears a guanidino group is independently guanidinoalkylene.
  • Embodiment 4 The compound of embodiment 1 or embodiment 2, wherein each substituent that bears a guanidino group is 3-guanidino-prop-1-yl.
  • Embodiment 5 The compound of embodiment 1 or embodiment 2, wherein each substituent that bears a guanidino group is 4-guanidino-but-1-yl.
  • Embodiment 6 The compound of embodiment 2, wherein the substituent that bears the first nucleobase, the substituent that bears the second nucleobase, and the substituent that bears the third nucleobase are each independently purinylacyl, purinylalkylene, pyrimidinylacyl, or pyrimidinylalkylene.
  • Embodiment 7 The compound of embodiment 2, wherein the substituent that bears the first nucleobase, the substituent that bears the second nucleobase, and the substituent that bears the third nucleobase are each independently guaninylacyl, adeninylacyl, cytosinylacyl, thyminylacyl, or uracilylacyl.
  • Embodiment 8 The compound of embodiment 2, wherein the first nucleobase, the second nucleobase, and the third nucleobase form a sequence that is CTG, TGC, or GCT.
  • Embodiment 9 The compound of any one of embodiments 1-8, wherein the compound is a peptide nucleic acid oligomer.
  • Embodiment 10 The compound of any one of embodiments 1-8, wherein the compound is a gamma peptide nucleic acid oligomer.
  • Embodiment 11 The compound of any one of embodiments 1-8, wherein the compound is a peptide nucleic acid oligomer, and the peptide nucleic acid oligomer comprises a series of nucleobase side chains that form a sequence that is (CTG) n , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 12 The compound of any one of embodiments 1-11, wherein the compound is a peptide nucleic acid oligomer, wherein the first end of the chain is an N-terminus of the peptide nucleic acid oligomer, and the second end of the chain is a C-terminus of the peptide nucleic acid oligomer.
  • Embodiment 13 The compound of embodiment 12, wherein the C-terminus of the peptide nucleic acid oligomer is bound by a peptide bond to the peptide.
  • Embodiment 14 The compound of embodiment 12, wherein the C-terminus of the peptide nucleic acid oligomer is bound by a peptide bond to an amidated lysine residue.
  • Embodiment 15 The compound of any one of embodiments 12-14, wherein an N-terminus of the peptide nucleic acid oligomer is unsubstituted.
  • Embodiment 16 The compound of any one of embodiments 12-14, wherein an N-terminus of the peptide nucleic acid oligomer is bound by a peptide bond to a peptide.
  • Embodiment 17 A compound comprising a peptide nucleic acid sequence and a cell permeabilizing group attached to the peptide nucleic acid sequence, wherein if a radiolabeled analogue of the compound is subjected to an assay, wherein the assay comprises:
  • Embodiment 18 The compound of embodiment 17, wherein the brain tissue is cortex tissue, caudate nucleus tissue, olfactory bulb tissue, putamen tissue, or thalamus tissue.
  • Embodiment 19 The compound of embodiment 17, wherein the brain tissue is cortex tissue, caudate nucleus tissue, olfactory bulb tissue, putamen tissue, and thalamus tissue.
  • Embodiment 20 The compound of embodiment 17, wherein in the assay, the concentration of the radiolabeled analogue in brain tissue determined in the second component is equivalent to at least about 100% of the concentration of the radiolabeled analogue in brain tissue determined in the first component.
  • Embodiment 21 The compound of embodiment 20, wherein the brain tissue of the sections is caudate nucleus tissue, olfactory bulb tissue, putamen tissue, or thalamus tissue.
  • Embodiment 22 The compound of embodiment 20, wherein the brain tissue of the sections is caudate nucleus tissue, olfactory bulb tissue, putamen tissue, and thalamus tissue.
  • Embodiment 23 The compound of embodiment 17, wherein in the assay, the concentration of the radiolabeled analogue in brain tissue determined in the second component is equivalent to at least about 150% of the concentration of the radiolabeled analogue in brain tissue determined in the first component.
  • Embodiment 24 The compound of embodiment 23, wherein the brain tissue of the sections is olfactory bulb tissue.
  • Embodiment 25 The compound of any one of embodiments 17-24, wherein the assay further comprises a third component, wherein the third component is analogous to the first component except that the second component uses another monkey that is euthanized 12 hours after the administering, wherein in the assay, the concentration of the radiolabeled analogue in brain tissue determined in the third component is equivalent to at least about 80% of the concentration of the radiolabeled analogue in brain tissue determined in the first component.
  • Embodiment 26 The compound of embodiment 25, wherein the brain tissue of the sections is cortex tissue, olfactory bulb tissue, putamen tissue, lateral ventricle tissue, or thalamus tissue.
  • Embodiment 27 The compound of embodiment 25, wherein the brain tissue of the sections is cortex tissue, olfactory bulb tissue, putamen tissue, lateral ventricle tissue, and thalamus tissue.
  • Embodiment 28 The compound of embodiment 25, wherein in the assay, the concentration of the radiolabeled analogue in brain tissue determined in the third component is equivalent to at least about 100% of the concentration of the radiolabeled analogue in brain tissue determined in the first component.
  • Embodiment 29 The compound of embodiment 28, wherein the brain tissue is olfactory bulb tissue or lateral ventricle tissue.
  • Embodiment 30 The compound of embodiment 28, wherein the brain tissue is olfactory bulb tissue and lateral ventricle tissue.
  • Embodiment 31 The compound of any one of embodiments 17-30, wherein the cell permeabilizing group is an alpha substituent of the peptide nucleic acid.
  • Embodiment 32 The compound of any one of embodiments 17-30, wherein the compound is a gamma peptide nucleic acid.
  • Embodiment 33 The compound of embodiment 32, wherein the cell permeabilizing group is a gamma substituent of the gamma peptide nucleic acid.
  • Embodiment 34 The compound of embodiment 33, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each independently guanidinoalkylene.
  • Embodiment 35 The compound of embodiment 33, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 3-guanidino-prop-1-yl.
  • Embodiment 36 The compound of embodiment 33, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 4-guanidino-but-1-yl.
  • Embodiment 37 The compound of any one of embodiments 17-36, wherein the peptide nucleic acid sequence is (CTG) n , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 38 The compound of any one of embodiments 17-37, wherein a C-terminus of the peptide nucleic acid is bound by a peptide bond to a peptide.
  • Embodiment 39 The compound of any one of embodiments 17-37, wherein a C-terminus of the peptide nucleic acid is bound by a peptide bond to an amidated lysine residue.
  • Embodiment 40 The compound of any one of embodiments 17-39, wherein an N-terminus of the peptide nucleic acid of the compound is unsubstituted.
  • Embodiment 41 A compound comprising a peptide nucleic acid sequence, wherein the peptide nucleic acid sequence comprises: (i) a series of peptide nucleic acid residues having a repeating triad of nucleobase side chains; and (ii) a cell permeabilizing group attached to the series of peptide nucleic acid residues, wherein if the compound is subjected to an assay, and the assay comprises:
  • Embodiment 42 The compound of embodiment 41, wherein the compound is a gamma peptide nucleic acid.
  • Embodiment 43 The compound of embodiment 42, wherein the cell permeabilizing group is an alpha substituent of the gamma peptide nucleic acid.
  • Embodiment 44 The compound of embodiment 42, wherein the cell permeabilizing group is a gamma substituent of the gamma peptide nucleic acid.
  • Embodiment 45 The compound of embodiment 43, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each independently guanidinoalkylene.
  • Embodiment 46 The compound of embodiment 43, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 3-guanidino-prop-1-yl.
  • Embodiment 47 The compound of embodiment 43, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 4-guanidino-but-1-yl.
  • Embodiment 48 The compound of any one of embodiments 41-47, wherein the peptide nucleic acid sequence is (CTG) n , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 49 The compound of any one of embodiments 41-48, wherein a C-terminus of the peptide nucleic acid sequence is bound by a peptide bond to a peptide.
  • Embodiment 50 The compound of any one of embodiments 41-48, wherein the C-terminus of the peptide nucleic acid sequence is bound by a peptide bond to an amidated lysine residue.
  • Embodiment 51 The compound of any one of embodiments 41-50, wherein an N-terminus of the peptide nucleic acid sequence of the compound is unsubstituted.
  • Embodiment 52 The compound of any one of embodiments 41-51, wherein if (1) the mice are male mice, the mean maximum brain concentration of the male mice is observed to be about 3110 ng/mL at the time to maximum brain concentration of about 1.5 hours and the dose amount of about 0.3 mg/kg, the mean maximum brain concentration of the male mice is observed to be about 6490 ng/mL at the time to maximum brain concentration of about 4 hours and the dose amount of about 0.6 mg/kg, and the mean maximum brain concentration of the male mice is observed to be about 15500 ng/mL at the time to maximum brain concentration of about 24 hours and the dose amount of about 1 mg/kg; and (2) if the mice are female mice, the mean maximum brain concentration of the female mice is observed to be about 3930 ng/mL at the time to maximum brain concentration of about 48 hours and a dose of about 0.3 mg/kg, the mean maximum brain concentration of the female mice is observed to be about 11400 ng/mL at the time to maximum brain concentration of about 1.5 hours and a dose of about 0.6
  • Embodiment 53 A compound comprising a peptide nucleic acid sequence, wherein the peptide nucleic acid sequence comprises: (i) a series of peptide nucleic acid residues having a repeating triad of nucleobase side chains; and (ii) a cell permeabilizing group attached to the series of peptide nucleic acid residues, wherein if the compound is subjected to an assay, and the assay comprises:
  • Embodiment 54 The compound of embodiment 53, wherein the compound is not observed at a detectable level during the month in the plasma, intestine, liver, lung, kidney, and muscle of the mice.
  • Embodiment 55 The compound of embodiment 53 or embodiment 54, wherein the compound is a gamma peptide nucleic acid.
  • Embodiment 56 The compound of embodiment 55, wherein the cell permeabilizing group is an alpha substituent of the gamma peptide nucleic acid.
  • Embodiment 57 The compound of embodiment 55, wherein the cell permeabilizing group is a gamma substituent of the gamma peptide nucleic acid.
  • Embodiment 58 The compound of embodiment 56, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each independently guanidinoalkylene.
  • Embodiment 59 The compound of embodiment 56, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 3-guanidino-prop-1-yl.
  • Embodiment 60 The compound of embodiment 56, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 4-guanidino-but-1-yl.
  • Embodiment 61 The compound of any one of embodiments 53-60, wherein the peptide nucleic acid sequence is (CTG) n , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 62 The compound of any one of embodiments 53-61, wherein a C-terminus of the peptide nucleic acid sequence is bound by a peptide bond to a peptide.
  • Embodiment 63 The compound of any one of embodiments 53-61, wherein the C-terminus of the peptide nucleic acid sequence is bound by a peptide bond to an amidated lysine residue.
  • Embodiment 64 The compound of any one of embodiments 53-63, wherein an N-terminus of the peptide nucleic acid sequence of the compound is unsubstituted.
  • Embodiment 65 A compound comprising a peptide nucleic acid sequence, wherein the peptide nucleic acid sequence comprises: (i) a series of peptide nucleic acid residues having a repeating triad of nucleobase side chains; and (ii) a cell permeabilizing group attached to the series of peptide nucleic acid residues, wherein if the compound is subjected to a plasma protein binding assay, and the plasma protein binding assay comprises:
  • Embodiment 66 The compound of embodiment 65, wherein in the plasma protein binding assay, the plasma protein binding percentage is at least about 85% in each of the human, mouse, dog, minipig, sheep, and monkey.
  • Embodiment 67 The compound of embodiment 65 or embodiment 66, wherein the compound is a gamma peptide nucleic acid.
  • Embodiment 68 The compound of embodiment 67, wherein the cell permeabilizing group is an alpha substituent of the gamma peptide nucleic acid.
  • Embodiment 69 The compound of embodiment 67, wherein the cell permeabilizing group is a gamma substituent of the gamma peptide nucleic acid.
  • Embodiment 70 The compound of embodiment 68, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each independently guanidinoalkylene.
  • Embodiment 71 The compound of embodiment 68, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 3-guanidino-prop-1-yl.
  • Embodiment 72 The compound of embodiment 68, wherein a plurality of gamma substituents of the gamma peptide nucleic acid are each 4-guanidino-but-1-yl.
  • Embodiment 73 The compound of any one of embodiments 65-72, wherein the peptide nucleic acid sequence is (CTG) n , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 74 The compound of any one of embodiments 65-73, wherein a C-terminus of the peptide nucleic acid sequence is bound by a peptide bond to a peptide.
  • Embodiment 75 The compound of any one of embodiments 65-73, wherein the C-terminus of the peptide nucleic acid sequence is bound by a peptide bond to an amidated lysine residue.
  • Embodiment 76 The compound of any one of embodiments 65-75, wherein an N-terminus of the peptide nucleic acid sequence of the compound is unsubstituted.
  • Embodiment 77 The compound of any one of embodiments 65-76, wherein at a concentration of about 1 ⁇ g/mL, the plasma protein binding percentage is at least about 95% in the human, mouse, dog, minipig, sheep, or monkey.
  • Embodiment 78 The compound of embodiment 77, wherein at the concentration of about 1 ⁇ g/mL, the plasma protein binding percentage is at least about 95% in each of the human, mouse, dog, minipig, sheep, and monkey.
  • Embodiment 79 A compound having the formula (I):
  • Embodiment 80 The compound of embodiment 79, wherein each B is independently guanine, thymine, or cytosine.
  • Embodiment 81 The compound of embodiment 79 or embodiment 80, wherein at least one R 1 is guanidino(C 1 -C 4 )alkyl.
  • Embodiment 82 The compound of any one of embodiments 79-81, wherein at least one R 2 is guanidino(C 1 -C 4 )alkyl.
  • Embodiment 83 The compound of any one of embodiments 79-82, wherein at least one R 1 is 4-guanidinobut-1-yl.
  • Embodiment 84 The compound of any one of embodiments 79-83, wherein at least one R 1 is 3-guanidinoprop-1-yl.
  • Embodiment 85 The compound of any one of embodiments 79-84, wherein at least one R 2 is 4-guanidinobut-1-yl.
  • Embodiment 86 The compound of any one of embodiments 79-85, wherein at least one R 2 is 3-guanidinoprop-1-yl.
  • Embodiment 87 The compound of any one of embodiments 79-86, wherein G is

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
US17/218,145 2020-03-30 2021-03-30 Modified peptide nucleic acid compositions Abandoned US20210309997A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US17/218,145 US20210309997A1 (en) 2020-03-30 2021-03-30 Modified peptide nucleic acid compositions
US17/232,001 US11603530B2 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/232,000 US20220112238A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,998 US20210309700A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,997 US20210324012A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US18/102,415 US20230174985A1 (en) 2020-03-30 2023-01-27 Modified peptide nucleic acid compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063002326P 2020-03-30 2020-03-30
US17/218,145 US20210309997A1 (en) 2020-03-30 2021-03-30 Modified peptide nucleic acid compositions

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US17/231,997 Continuation US20210324012A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/232,001 Continuation US11603530B2 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,998 Continuation US20210309700A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/232,000 Continuation US20220112238A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions

Publications (1)

Publication Number Publication Date
US20210309997A1 true US20210309997A1 (en) 2021-10-07

Family

ID=77921451

Family Applications (6)

Application Number Title Priority Date Filing Date
US17/218,145 Abandoned US20210309997A1 (en) 2020-03-30 2021-03-30 Modified peptide nucleic acid compositions
US17/232,000 Abandoned US20220112238A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,997 Abandoned US20210324012A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/232,001 Active US11603530B2 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,998 Abandoned US20210309700A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US18/102,415 Pending US20230174985A1 (en) 2020-03-30 2023-01-27 Modified peptide nucleic acid compositions

Family Applications After (5)

Application Number Title Priority Date Filing Date
US17/232,000 Abandoned US20220112238A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,997 Abandoned US20210324012A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/232,001 Active US11603530B2 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US17/231,998 Abandoned US20210309700A1 (en) 2020-03-30 2021-04-15 Modified peptide nucleic acid compositions
US18/102,415 Pending US20230174985A1 (en) 2020-03-30 2023-01-27 Modified peptide nucleic acid compositions

Country Status (6)

Country Link
US (6) US20210309997A1 (ja)
EP (1) EP4127228A4 (ja)
JP (1) JP2023520405A (ja)
AU (1) AU2021246046A1 (ja)
CA (1) CA3173015A1 (ja)
WO (1) WO2021202621A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11603530B2 (en) 2020-03-30 2023-03-14 Neubase Therapeutics, Inc. Modified peptide nucleic acid compositions
WO2023244536A3 (en) * 2022-06-13 2024-03-28 Neubase Therapeutics, Inc. Oligonucleotide analogue formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200318195A1 (en) * 2017-12-21 2020-10-08 Carnegie Mellon University Bivalent Nucleic Acid Ligands and Uses Therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
US7960360B2 (en) 2006-11-13 2011-06-14 Jennifer Rubin Grandis Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents
JP2011529686A (ja) * 2008-07-29 2011-12-15 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ポリグルタミンタンパク質発現の選択的阻害
WO2015172058A1 (en) 2014-05-08 2015-11-12 Carnegie Mellon University Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor
WO2020172664A1 (en) * 2019-02-22 2020-08-27 Carnegie Mellon University Tuning binding cooperativity in nucleic acid targeting compounds
EP4127228A4 (en) 2020-03-30 2024-05-29 Neubase Therapeutics Inc MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200318195A1 (en) * 2017-12-21 2020-10-08 Carnegie Mellon University Bivalent Nucleic Acid Ligands and Uses Therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lu, X. W. (2010). Synthesis and properties of amino- and guanidino-peptoid peptide nucleic acids. Doctoral thesis, Nanyang Technological University, Singapore. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11603530B2 (en) 2020-03-30 2023-03-14 Neubase Therapeutics, Inc. Modified peptide nucleic acid compositions
WO2023244536A3 (en) * 2022-06-13 2024-03-28 Neubase Therapeutics, Inc. Oligonucleotide analogue formulations

Also Published As

Publication number Publication date
US20220112238A1 (en) 2022-04-14
US20220324914A1 (en) 2022-10-13
CA3173015A1 (en) 2021-10-07
EP4127228A2 (en) 2023-02-08
JP2023520405A (ja) 2023-05-17
US20230174985A1 (en) 2023-06-08
WO2021202621A2 (en) 2021-10-07
AU2021246046A1 (en) 2022-10-13
EP4127228A4 (en) 2024-05-29
US20210324012A1 (en) 2021-10-21
WO2021202621A3 (en) 2021-11-11
US11603530B2 (en) 2023-03-14
US20210309700A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20230174985A1 (en) Modified peptide nucleic acid compositions
Litwin et al. Wilson disease—treatment perspectives
US7994329B2 (en) Growth hormone secretagogue receptor type 1A agonists
US11027029B2 (en) Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer
EA037778B1 (ru) Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы
US20210188784A1 (en) 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting asm activity, and use thereof
JP2020511459A (ja) 軟骨ホーミングペプチドコンジュゲート及びその使用方法
Akizawa et al. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo
US10494401B2 (en) LLP2A-bisphosphonate conjugates for osteoporosis treatment
KR20200011485A (ko) 섬유증 치료를 위한 조성물
US20230211000A1 (en) Tissue-homing peptide conjugates and methods of use thereof
JP2018008955A (ja) Ｓｈｋベースの薬学的組成物とその製造方法および使用方法
EA031399B1 (ru) Изготовление и использование пероральных фармацевтических композиций на основе митохондриально-адресованных антиоксидантов
Cikrt et al. Excretion of cadmium through bile and intestinal wall in rats
US20130210883A1 (en) Lipase inhibitors
US20230364244A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
US6734166B1 (en) Method of reducing aluminum levels in the central nervous system
US9999690B2 (en) Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
Reddiar et al. A biodistribution study of the radiolabeled kv1. 3-blocking peptide DOTA-HsTX1 [r14a] demonstrates brain uptake in a mouse model of neuroinflammation
US20080255051A1 (en) Novel Peptides That Promote Lipid Efflux
US20060035946A1 (en) Amyloid-binding, metal-chelating agents
US20210386874A1 (en) Compositions and methods for measuring oxidative stress
US20230310330A1 (en) Peptidic oligomers and methods of using the same
WO2013111759A1 (ja) ステルス性かつ高尿排泄性のコラーゲン様ペプチド
DE10305463A1 (de) Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUBASE THERAPEUTICS, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LY, DANITH H.;THADKE, SHIVAJI;BACKENROTH, SAMUEL I.;AND OTHERS;SIGNING DATES FROM 20190201 TO 20210411;REEL/FRAME:055953/0717

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: NEUBASE THERAPEUTICS, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THADKE, SHIVAJI A.;SOOTER, LETHA J.;SIGNING DATES FROM 20220607 TO 20220608;REEL/FRAME:060409/0670

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION